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 welcome to Fusion
Dear George Washington Medical Community, Faculty, and Students:
Welcome to the 2011 edition of Fusion, a com-
pletely student-run research journal by The 
George Washington University’s William H. 
Beaumont Medical Research Honor Society at 
GW’s School of Medicine and Health Science 
(SMHS). Beaumont aims to promote the value 
of research for students in the medical commu-
nity. Among our activities, including journal 
clubs and Research Day, the most rewarding 
aspect of this society is working with our 
classmates and future colleagues to publish this 
journal.
Fusion is aptly named: the journal embodies 
the link between science and medicine, as 
articles span the gamut of scientific disciplines 
and clinical subspecialties both domestic and 
abroad. In medicine, hard science and bench 
research yield clinical trials, which in turn 
guide bedside practices and public health cam-
paigns. Our journal features student research 
and perspectives in all of these phases, which 
is in part what makes medicine such a col-
laborative and exciting field. As busy medical 
students, it often becomes easy to approach 
our studies as a block of knowledge to memo-
rize; but when we engage in research projects 
and discussions with classmates, we find that 
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the process of learning can and should be a 
dynamic one. This is what Fusion is all about 
— student interest in research — the very 
thing that moves medicine forward. 
The theme of GW Research Day and this 
magazine is advancing cancer research. Our 
cover image was created by Kenneth Morford, 
MSII. Through a multimedia piece, Morford’s 
depiction represents the importance of interdis-
ciplinary collaboration in medical research and 
highlights the art of medicine. 
Finally, we would like to take this opportu-
nity to acknowledge and thank our new faculty 
advisor, Vincent A. Chiappinelli, PhD, interim 
associate vice provost for Health Affairs, and 
associate dean of SMHS. His guidance and 
enthusiasm throughout the year has provided 
us with inspiration and a sense of purpose. 
We are very proud of this edition of Fusion 
and the hard work that our colleagues put forth 
into creating this magazine. It is our hope that 
you will find as much enjoyment and inspira-
tion flipping through the following pages as we 
did editing them. 
Your editors, 
Eric, Gena, Jana, Kristen, Stephen, and Thomas
1Fusion ✦ 2011
FROM THE DEAN’S OFFICE
The Practice of Medicine: A Balance Between Art and Science
Vincent A. Chiappinelli, PhD,  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 2
ADVICE FROM AN EXPERT
The Researcher’s Art is First of All to Find Himself a Good Boss.
Jeremy Brown, MD. . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . p. 3
PERSPECTIVES
Earth’s Chief Complaint: Climate Change
Rachel Harold, MSII . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . p. 4
To Tell or Not to Tell: On Disclosing the Diagnosis of Dementia
Ayhan Yoruk, MSI . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . p. 5
Sherley Pétion: A Resilient Spirit in the Midst of the Devastation in Haiti
Jeffanne Millein, MSII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 6
BASIC SCIENCE
Brain Structural Evidence of Epistasis Between RGS4 and COMT Variations 
in Schizophrenia
Marc Lener, MSIV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 7
Identification of microRNAs Differentially Expressed in Urothelial Carcinoma
Yasmin Akbari, MSI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 8
Using a FACS-based Assay to Measure Dengue Virus Infection  
of DC- and L-SIGN Cells in the Presence of Neutralizing Antibodies 
Kate Poropatich, MSII.  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . p. 9
Brain Tumor Stem Cells Isolated from a RasB8 Transgenic Murine 
Model Provide a Working Stem Cell Model for Malignant Glioma
Kristen Batich, MSII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 10
Cystathionine-γ-Lyase: A Target for Septic Shock
Monica Gupta, MSIII. .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . p. 12
In Vivo Persistence of Redirected T Cells Transduced at Decreased Oxygen Concentrations
Gena Gora, MSII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 13
In Vivo Imaging of the Cannabinoid CB1 Receptor Using Positron Emission Tomography
Garth Terry, MSIV, PhD . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . p. 15
Spontaneous Uveitis in the Absence of IFN-g in Transgenic 
Mice Expressing a Retina-specific T cell Receptor
Neena Passi, MSII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 16
CLINICAL PRACTICE
Appropriate Role of Aprotinin in Thoracic Aortic Surgery: Should We Have it Back?
Andrew Zhang, MSII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 18
Use of Musculoskeletal Ultrasound to Diagnose and Treat 
Symptomatic Sacral Bursitis: A Case Report
Matthew Bean, MSIII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 19
Robotic Radiosurgery for Inoperable Patients with Peripheral Stage IA  
Non-Small Cell Lung Cancer: Local Control and Survival Using 5-mm Margins
Beant Gill, MSIV  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 20
Demographics of Pulmonary Complications in Sickle Cell Disease
Kathy Chyjek, MSII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 21
Flat Blood Pressure Response to Exercise in Patients  
with the Total Artificial Heart: The Feasibility of Cardiac Rehabilitation
Harajeshwar Singh Kohli, MSII .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . p. 22
Enoxaparin Treatment for Cerebral Venous Thrombosis in a Pediatric Patient
Waleed Kurtom, MSIII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 24
CyberKnife Radiosurgery for Previously Irradiated Vaginal Tumors
Huma Chaudhry, MSII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 25
Bi-Rads Subcategorization as a Useful Predictor of Malignancy
Kerri Vincenti, MSI . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . p. 26
Occupational Radiation Exposure of Interventional Radiologists   
and Staff During Performance of Biopsies Guided by CT Fluoroscopy
Sagine Berry-Tony, MSII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 27
High Levels of Intra-tumoral Tumor-infiltrating Lymphocytes and No 
Angiolymphatic Invasion Increase Recurrence-free Survival in Stage 1A NSCLC
Zach Horne, MSII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 28
Functional and Structural Connectivity of Cognition (Language 
and Working Memory) in Children with Epilepsy
Meera Cheerharan, MSII . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . p. 30
25-OH Vitamin D Levels in Patients with Retinal Pathology: A Retrospective Study
Atif Mohiuddin, MSII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 31
PUBLIC HEALTH
Strengthening the Safety Net: Evaluating Access to Primary Care  
in the Emergency Department
Anna Dill, MSII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 32
Head Injury and Posttraumatic Stress Disorder Among Those Present South  
of Chambers Street in Manhattan During the Sept. 11, 2001 Terrorist Attacks
Sarah Mohajeri, MSII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 33
Traditional Birth Attendants: A Non-Traditional Way to Improve Access to Prevention 
of Mother-to Child HIV Transmission Efforts among Women in Rural Southern India
Jana Freeman, MSII  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 35
A Sociocultural Evaluation of Neglected Tropical Diseases and Deworming 
Campaign Efforts in Northern Rwanda
Lindsay Wheeler, MSII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p. 36
table of contents
Fusion ✦ 20112
 from the dean’s office
It has been a pleasure to serve as the faculty advisor to the William H. Beaumont 
Medical Research Honor Society. The Beaumont Society is a student-run organization 
that brings together students with a very wide range of research interests and 
experiences, from basic biomedical research to clinical studies to health policy research. 
Fusion is the showcase for these students’ work, and this year’s edition is a fascinating 
window into their research world. 
Medicine is both art and science, and gaining experience in both of these aspects 
of the field is rewarding and can lead in unexpected directions. I recommend going 
with what you find most interesting. An early interest in the development of the 
nervous system triggered my studies of nicotinic acetylcholine receptors. Finding a 
lack of drugs that could be used as probes for these neuronal receptors, I began to 
isolate proteins from snake venom and test their potencies as antagonists at these 
receptors. This led to the discovery of kappa-bungarotoxin. To gain more insight into 
how this toxin blocked nicotinic receptors I travelled to parts of China and Taiwan 
where these poisonous snakes live, and working with my collaborators I was able to 
purify additional kappa-neurotoxins. You never know where your research will take 
you, but it is challenging, often fun, and surprisingly social as interactions with other 
scientists are essential in cutting-edge research.
Medical students have a long tradition as biomedical researchers. It was a medical 
student who in 1846 first publicly demonstrated the remarkable value of ether as a 
general anesthetic. The research experiences of our GW medical students described 
in Fusion are the result of hard work, major successes and minor disasters, and above 
all a dedication to push the window so that science can inform decision making for 
both medical doctors and our society. The faculty members of SMHS congratulate 
the students of the Beaumont Society and express our warmest wishes for your future 
journeys through art and science.
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LETTERS 3
The Researcher’s Art is First of All to Find Himself a Good Boss.
Jeremy Brown, MD, 
associate professor of 
Emergency Medicine, GW 
School of Medicine and 
Health Sciences
This issue of Fusion is a celebration of the vibrant research community that flourishes 
at The George Washington University. In any medical student’s busy life it can be hard 
to find the time to do anything other than study and absorb pages of information; 
but the number of students who have not only found time to become involved with 
research, but also have had the patience and fortitude to see their projects through 
to the stage of presentation is quite remarkable. Now, where do you go from here?
For some of you it will be enough to have participated in your project and you may 
have decided, upon reflection, that research is not going to be your final career choice. 
For others, this opportunity may have resulted in the opposite conclusion. But whether 
you focus on clinical practice or research, your success will likely depend on following 
André Lwoff ’s advice: find yourself a good boss. Lwoff was a French physician and 
microbiologist and was awarded the Nobel Prize in Medicine in 1965 for his discovery 
that some viruses infect bacteria. Lwoff also knew a thing or two about finding a good 
boss — or in the language that we use today — a good mentor; early in his career he 
spent a spent a year working for Otto Meyerhof — also a Nobel Prize winner — in 
Heidelberg. Having spent at least four years being mentored (and sometimes perhaps 
bossed, too) you will have seen many different styles of both teaching and treating. 
Your greatest ticket to success is to emulate the very best practices that you have seen 
and consciously shun those that you observed to be counter productive. Did your 
mentor use a line with a patient that seemed to work well? If so, use it yourself. And 
if you saw an empathetic physician reach out to a patient, copy that technique and 
pass it on. When it comes to research this advice is just as important. To be a great 
researcher you need a boss who can be a role model — someone you can both emu-
late and to whom you can reach out. This goal is of course a lofty one; mentors and 
leaders after all are only human, and they may have great skills in one area but be 
utterly wanting in others. That is why I suggest amending Lwoff ’s advice. Don’t find 
one good boss or mentor, but rather several, and take the very best traits from each. 
Many years ago, while a medical student in London, I read a long piece in the 
London Times by a distinguished Professor of Medical Ethics that outlined the reasons 
why research on human embryos should be banned. Rather naïvely, I wrote an equally 
long piece on what I considered to be the flaws in the argument, and discussed it with 
a mentor of mine who not only showed me the problems with my own reasoning, but 
encouraged me to publish the piece. Thanks to his mentorship I did precisely that. It 
was not perhaps a Nobel Prize winning publication, but the mentorship and advice 
was worth a lot more than the two lines the article took up on my resume, because 
it showed me how it was possible to become involved even as a young student, in the 
conversation and research that shapes the society in which we live. As young physi-
cians and researchers you will have an important role in shaping the society in which 
you choose to make your homes. So choose your next boss wisely, for whether you 
will become a Nobel Prize winner or an excellent and compassionate physician, your 
boss — or bosses — will have a key role to play.
Cited in Max Perutz, Is science necessary? Essays on Science and scientists, (1991), 194.
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As global climate 
change continues 
to  impac t  the 
environment in 
which we l ive, 
huma n hea lt h 
i s  and wi l l  be 
deeply affected. 
Di re c t  he a l t h 
impacts may take 
numerous forms: 
increased extreme 
heat events like 
the one that killed 
approximately 30,000, mostly elderly, 
people in Europe in 2003;1 expanding 
geographic and seasonal ranges of vector-
borne diseases such as Dengue; increased 
frequency of severe weather events such 
as hurricanes; and respiratory illnesses 
such as asthma due to changes in air 
quality. In addition, there will be health 
implications that result indirectly from 
climate change such as the morbidity 
and mortality associated with food and 
 perspectives
by reducing greenhouse gas emissions, 
shifting the paradigm away from preven-
tative policy change and focusing efforts 
on adaptation strategies to help global 
citizens handle the expected impacts of 
climate change. From 
a health perspective, 
inaction on climate 
change is especially 
imprudent because 
there are many positive 
health outcomes asso-
ciated with reducing 
greenhouse ga se s . 
These “co-benef its” 
(and occasional “co-
harms”) are expected 
to result from changes 
that our global society 
makes to respond to climate change. For 
example, if communities increase public 
transportation infrastructure and create 
more systems for walking and biking 
in their built communities to reduce 
greenhouse gas emissions from cars, then 
the incidence of health problems such as 
obesity and cardiovascular disease will 
be reduced due to increased exercise. 
Another example includes replacing 
pervasive dirty biomass-burning indoor 
cook-stoves in countries such as India 
with low emission cook-stoves. Climate-
altering emissions would be reduced, but 
so too would cases of chronic obstructive 
pulmonary disease, acute lower respira-
tory infections in children, and ischemic 
heart disease that are exacerbated and 
sometimes caused by indoor air pol-
lution. In November 2009, the Lancet 
released a series that quantitatively mod-
eled these and other predicted public 
health outcomes of specific strategies 
to reduce climate change. The results 
suggested significant short-term health 
benefits while reducing future health, 
economic, and ecosystem risks. 
While political leaders may be 
responding slowly to the climate issue, 
the scientific and health communities 
are working hard to manage and prevent 
widespread health disasters. For example, 
the Group on Earth Observations is 
using satellite technology to monitor 
drought conditions in sub-Sahara Africa 
Rachel  Harold,  MSII 
Advisor: John Balbus, MD, 
MPH, National Institute 
of Environmental Health 
Sciences
Earth’s Chief Complaint: Climate Change
While the issue of climate change may 
appear static in the halls of Congress and the 
summits in Copenhagen and Cancun, it is 
certainly moving into our exam rooms and 
hospitals. Clinics across the world will soon 
be full of patients with a chief complaint of 
climate change.
water insecurity resulting from droughts 
and floods. Climate change is expected 
to take many of the health issues we 
already can’t control and increase their 
frequency, their reach, and their severity.2 
Unfortunately, many global leaders 
have been hesitant to take bold steps to 
mitigate the impacts of climate change 
Art by Kenneth Morford, MSII
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which often precede major meningitis 
outbreaks. Meanwhile, the National 
Institutes of Health and the Centers 
for Disease Control and Prevention are 
working to create a cohesive national 
research agenda and help individual 
communities prepare for the health chal-
lenges of climate change, some of which 
may be new to American soil. 
While the issue of climate change 
may appear static in the halls of Congress 
and the summits in Copenhagen and 
Cancun, it is certainly moving into our 
exam rooms and hospitals. Clinics across 
the world will soon be full of patients 
with a chief complaint of climate change.
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To Tell or Not to Tell: On Disclosing the Diagnosis of Dementia
As the number of 
older persons (age 
65 and older) in 
the United States 
c o n t i n u e s  t o 
rapidly rise, par-
ticularly with the 
imminent aging 
of the baby boom 
generation, there 
will be a signifi-
cant increase in 
the incidence of 
age-related Alzheimer’s disease. An 
incurable, degenerative, and terminal 
disease, Alzheimer’s currently inflicts 
more than 35 million individuals world-
wide and its prevalence is projected to 
reach approximately 107 million by 
the year 2050.1 Given the major impact 
of the diagnosis of Alzheimer’s disease 
on not only the patients, but also their 
family and caregivers, the medical practi-
tioners’ attitudes and practices regarding 
the disclosure of diagnosis, as related to 
the field of dementia, is of great concern. 
Should physicians communicate a 
diagnosis of Alzheimer’s disease to their 
patients? Physicians show great variation 
in practice, with fewer than half of clini-
cians regularly reporting a diagnosis of 
Alzheimer’s to their patients.2 Weighing 
the effect of the decision on patients, 
families, physicians, and the larger health 
care system as we evaluate the reasons 
for telling or not telling, this brief will 
Ay h a n  Yo r u k ,  M S I 
Adv i so r :  V i c to r ia  H. 
Raveis, PhD, Mailman 
School of Public Health, 
Columbia University
outline the importance of straightfor-
ward communication. 
The arguments that have typically 
been put forth against diagnostic disclo-
sure are based largely on the principle of 
non-maleficence, which is the obligation 
to avoid harm. The emphasis on avoiding 
harm to patients has relied on (1) the 
lack of absolute diagnostic certainty 
without post-mortem clinical informa-
tion, (2) the fact that treatment options 
are limited, and there is no cure, (3) the 
questionable ability of patients, par-
ticularly those in advanced stages of the 
disease, to understand the implications 
of the diagnosis, and (4) the potential for 
adverse, or even catastrophic, psycho-
logical responses to diagnostic disclosure 
as their justification.3
The arguments that have typ-
ically been put forth in sup-
port of diagnostic disclosure are 
based largely on the principle 
of providing the care that the 
patient deserves (justice) and patient 
autonomy. “Positive reasons for 
disclosure range from ‘the patient’s 
right to know’ and facilitation of 
future planning to ‘taking that 
once in a lifetime holiday.’ ”2 
Of particular importance is 
the framework within which 
target symptoms and symptom-
atic treatment options can be 
discussed3 as well as opportu-
nities to learn of and engage 
in therapeutic and clinical trials.5
It is my view that all medical pro-
fessionals should adopt the practice of 
absolute truth-telling. There are many 
rational reasons for non-disclosure, but 
there is a lack of evidence supporting that 
it is more beneficial than truth-telling. 
Many believe that the negative outcomes 
anticipated by physicians and caregivers 
alike are worse than that evidenced in 
reality. In fact, literature supporting 
the diagnostic disclosure of Alzheimer’s 
disease is increasing.
DEMENTIA Continued on p. 6
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A campaign to convince medical 
practitioners of the benefits of disclosing 
the diagnosis of dementia, particularly 
when compared to the disadvantages, 
may prove highly successful in promoting 
the absolute disclosure of diagnoses. This 
may be accomplished through advocacy 
via medical professional organizations 
or even publishing studies weighing the 
pros and cons of disclosing the diagnosis 
of dementia. Moreover, a campaign to 
train medical professionals on when 
and how to tell their patients may prove 
beneficial, as well as breaking common 
misconceptions and fears of disclosing 
DEMENTIA Continued from p. 5 the diagnoses. The failure to diagnose 
and treat persons with Alzheimer’s 
disease is commonly attributed to the 
lack of physicians’ knowledge about 
dementing illnesses, the absence of 
cognitive screening and the public 
perception that nothing can be done 
about the disease.6 Further research and 
advancements in fields exploring the 
aforementioned limitations is highly 
recommended, particularly as our society 
readies itself for the rapidly growing 
aging-population.
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Sherley Pétion: A Resilient Spirit in the Midst of the Devastation in Haiti
Her name was 
Sherley Pétion. 
A native of Port-
au-Prince, Haiti, 
she was a nurse 
working with me 
for the summer. 
The first time we 
met, she was in 
her white scrubs, 
carefully feeding a 
premature infant 
from a dropper. 
She barely looked up as I introduced 
myself, so absorbed in her work that 
an introduction was really a minimal 
priority. One afternoon, with all work 
done for the day, we remained in the 
delivery room waiting for labor or emer-
gency cases. She sat in her usual seat, a 
white chair, near the door-less dressing 
room. We were talking about mundane 
things when she revealed how she had 
lost everything during the earthquake. 
A month prior, she was planning her 
wedding to the “perfect guy.” She paused 
briefly as the painful memory overtook 
her. The soft lines under her eyes creased 
and the scar near her left eye seemed to 
cringe at the next few words. “He died 
suddenly a month before the earthquake. 
Just like that,” she said softly. Then a 
couple of weeks later the earthquake 
hit and completely destroyed her home. 
She fled from the capitol and moved in 
with her cousin who lived in St. Louis 
du Nord, in northwest Haiti. Sherley 
described how she was despondent and 
barely able to function. Yet despite it 
all, she gradually found pieces of herself 
in her work. The premature infant she 
was caring for was able to go home, a 
healthy and growing little boy—all due 
to the time and compassion that Sherley 
showed in caring for him.
This clinic in St. Louis du Nord 
was a mere eight miles from where I 
grew up. My research focused on pre-
eclampsia and eclampsia care in a rural 
setting, surveying the different stresses 
in patients’ lives, how often they accessed 
care during their term and difficulties 
encountered getting to the clinic. We 
discovered that many of the women 
travelled long distances at early hours 
to secure doctor appointments. Many 
patients were young and barely educated. 
Most women lacked the financial means 
to properly take care of themselves and 
hence had underlying problems with 
their pregnancies. Even with diet 
recommendations and proper sex 
education, patient compliance 
remained low due to lack of 
resources. However, for many 
of the women who come, they 
receive quality care for most of their ail-
ments and usually give birth to healthy 
babies.
I initially thought that I would go 
to Haiti having something to offer. But 
it was my interactions with the people I 
met and the relationships we built that 
contributed the most to my learning 
experience. Their resilience and refusal 
to stop living despite their difficult lives 
have muted my protests with struggles 
encountered in medical school and 
beyond. From Sherley’s story to the 
mother who still has trouble recovering 
from losing a child a year ago, I have 
found a broader sense of purpose in my 
aspirations of becoming a physician. 
Their courage 
has inspired 
me to  be 
better.
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Brain Structural Evidence of Epistasis Between RGS4 and COMT  
Variations in Schizophrenia
Schizophrenia is 
a debilitating psy-
chiatric disorder 
with a worldwide 
pr e v a l enc e  o f 
1%. Clinically, 
schizophrenia is 
characterized by 
thought disorder, 
lack of emotional 
responsiveness, 
auditory halluci-
nations, and paranoid delusions. With 
heritability calculated at 81%, genetic 
association studies have identified sev-
eral susceptibility loci and numerous 
genes linked to schizophrenia.3,6 Among 
the most signif icant candidate risk 
genes for schizophrenia, polymor-
phisms of the Catechol-O-methyl trans-
ferase (COMT) and the Regulator of 
G-protein Signaling 4 (RGS4) demon-
strate great potential to act interactively 
in schizophrenic patients.1,4,5
The membrane-associated isotype 
of COMT is responsible for catalyzing 
the inactivation of dopamine and is 
found mainly in the prefrontal cortex 
and hippocampus. RGS4 is a GTPase 
activator that acts to inhibit Gi/o and 
Gq, resulting in the attenuation of dopa-
minergic signal transduction at specific 
dopamine receptors. Interestingly, a 
reciprocal interaction occurs such that 
RGS4 gene expression is regulated by 
the increased activation of the GPCRs 
it modulates. Based on previously found 
interactions between both RGS4 and 
COMT2,6,7 studies investigating func-
tional epistasis of RGS4 and COMT 
in schizophrenic patients showed pre-
frontal cortical and hippocampal dys-
regulation in association with abnormal 
dopamine signaling1 consistent with a 
dopamine hypothesis for schizophrenia. 
In our study, we evaluated our samples 
for similar associations and, in addition, 
examined epistatic interactions of RGS4 
polymorphisms on grey matter volumes 
among patients and healthy subjects. 
We examined structural MRI scans 
from 21 first-episode, antipsychotic-
naïve schizophrenia or schizoaffective 
disorder subjects and 19 healthy sub-
jects using tests for interaction using 
voxel-based morphometry to examine 
grey matter alterations associated with 
COMT and RGS4 risk alleles both 
independently and interactively. We 
observed RGS4 and COMT interac-
tions in the posterior cingulate, insular, 
occipital, and temporal regions. The 
most consistent f inding among all 
interactions was grey matter reductions 
at the inferior and superior temporal 
gyri, corresponding to the heteromodal 
association areas (See Figure). 
Our observations suggest that RGS4 
and COMT variations are independently 
and epistatically associated with grey 
matter reductions at the dorsal compo-
nents of heteromodal association areas, 
a collection of interconnected network 
of neural circuits that may be affected by 
genetically determined neurodevelop-
mental abnormalities in schizophrenic 
patients. Previous associations of func-
tional interaction between COMT and 
RGS4 with altered working memory 
performance and Blood Oxygen-Level 
Dependence (BOLD) responses at the 
prefrontal cortex in SZ may be mediated 
FIGURE: Glass brain pictures and rendering on to T1 image. Shaded Areas- voxels demonstrating RGS4 and COMT 
interaction via grey matter volumetric reduction with significance of p < 0.01. Blue Areas - significant voxels at p < 0.001.
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by dopamine associated neurotoxic and 
neurotrophic structural changes in the 
dorsal heteromodal association areas. 
Although the exact mechanism of 
pathogenesis of schizophrenia has not 
been established, numerous underlying 
neurobiological mechanisms provide 
insight into its complex disease process. 
In contrast to simple Mendelian inheri-
tance, the development of schizophrenia 
is determined by a complex interaction 
among multiple genes and environ-
mental factors, including socioeco-
nomic circumstances, education, family 
structure, life stresses, and maternal-
fetal exposure to infection. Therefore, 
emergence of psychopathology is rooted 
in the interplay between genes and 
environment and can be seen at the 
level of molecular and cellular altera-
tions resulting in dysregulations in 
neural circuitry. The advancement of 
psychiatric genetics, brain imaging, 
cognitive and affective neuroscience, 
and psychometric theory has furthered 
our understanding of the etiology and 
pathophysiology of psychiatric disorders 
such that new treatment interventions 
can be utilized. 
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Identification of microRNAs Differentially Expressed in Urothelial Carcinoma
Bladder cancer 
is currently the 
f o u r t h  m o s t 
common cancer 
type in the United 
States, with over 
7 0 , 0 0 0  n e w 
cases and 14,000 
deaths reported in 
2009.1 Urothelial 
carcinoma (UC), 
the most common 
form of bladder 
cancer, affects the inner epithelial lining 
of the bladder and, in severe instances, 
invades the outer muscle layers. While in 
most cases UC presents as a noninvasive 
papillary tumor with good prognosis, 
such low-grade urothelial tumors are 
known for their high rate of recurrence,2 
making them difficult and expensive to 
treat.
MicroRNAs (miRNAs) are a recently 
discovered class of short, non-coding 
RNA molecules responsible for post-
transcriptional fine-tuning of human 
gene regulation. Notably, miRNAs 
appear to demonstrate differential 
expression levels across various stages 
of cancer and thus may play a role 
in tumorigenesis, serving as either 
oncogenes or tumor-suppressor genes. 
Current research has shown that the 
expression signature of miRNAs tends 
to remain fairly consistent between cells 
of a particular type and cancer stage,3 
suggesting that a panel of miRNAs 
differentially expressed in malignant 
tissue may serve as diagnostic markers 
for a given cancer type.
In this study, we propose such a 
diagnostic panel of miRNAs that may 
supplement existing UC diagnostic tests. 
UC is traditionally diagnosed following 
cystoscopy accompanied by histological 
examination of urothelial tissue biopsy, 
yet these methods do not always offer a 
clear distinction between normal and 
cancer phenotypes. Analysis of miRNA 
expression in urothelial tissue may serve 
as a powerful quantitative supplement 
to largely qua litat ive cystoscopy 
examinat ion, thereby improving 
confidence in diagnosis of UC.
RNA was extracted from 23 patient 
tissue samples (eight normal urothelium, 
eight high-grade UC, seven low-grade 
UC) and quantified using RT-PCR. 
Expression data was normalized using 
U6 as an endogenous control. A two-
tailed t-test revealed a panel of 20 
miRNAs differentially expressed in UC 
tissue (p < 0.05), with 11 down-regulated 
and the remaining nine up-regulated. 
Among these 20 miRNAs, miR-143 
appears down-regulated, supporting 
existing research that implicates miR-
143 as a tumor suppressor in bladder 
cancer.4 K-Nearest Neighbors and Naive 
Bayes classifiers were generated using 
this miRNA panel and demonstrated 
reasonably high sensitivity (0.93 and 
0.87, respectively) and specificity (0.88 
and 1.00, respectively) in diagnosing 
UC. ROC curves for each classifier 
also suggested performance well above 
random guessing and with high accuracy. 
However, the majority of the miRNAs 
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 miRNA p-value Fold Change Expression in Cancer
 hsa-miR-125a 0.026 0.227 Lower
 hsa-miR-125b 0.042 0.312 Lower
 hsa-miR-127 0.042 0.406 Lower
 hsa-miR-138 0.014 21.859 Higher
 hsa-miR-143 0.048 0.276 Lower
 hsa-miR-146a 0.066* 0.305 Lower
 hsa-miR-197 0.018 0.460 Lower
 hsa-miR-198 0.032 0.370 Lower
 hsa-miR-222 0.022 0.228 Lower
 hsa-miR-23a 0.048 0.399 Lower
 hsa-miR-365 0.042 26.052 Higher
 hsa-miR-375 0.016 0.097 Lower
 hsa-miR-376a 0.018 0.186 Lower
 hsa-miR-515-5p 0.028 25.516 Higher
 hsa-miR-521 0.047 6.176 Higher
 hsa-miR-569 0.040 26.237 Higher
 hsa-miR-587 0.020 22.454 Higher
 hsa-miR-611 0.006 9.962 Higher
 hsa-miR-96 0.024 5.195 Higher
TABLE: 20 miRNAs differentially expressed in urothelial carcinoma (UC) tissue as compared with normal urothelium. 
All miRNA fold increases/decreases are significant (p<0.05) with the exception of hsa-miR-146a marked with an (*).
that comprise this panel (16 out of the 
20) have not been implicated in UC 
or any other urological cancers when 
queried in PubMed. Currently our 
collection of 20 miRNAs performs well 
as a diagnostic panel for UC in our 
patient set and may be appropriate for 
larger populations. Future studies will 
need to explore any causative role of these 
20 miRNAs in UC via cell culture study 
and analysis of potential gene pathway 
targets in order to help confirm their 
diagnostic validity. 
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Using a FACS-based Assay to Measure Dengue Virus Infection  
of DC- and L-SIGN Cells in the Presence of Neutralizing Antibodies 
Den g ue  v i r u s 
( DE N V )  i s  a 
worsening arbo-
v i r a l  d i s e a s e 
endemic to coun-
tries in Central 
a n d  S o u t h 
America, Africa, 
and South and 
Southeast Asia. 
Mechanisms of 
DE N V i n f e c -
tion and disease 
pathogenesis 
remain incom-
ple te ly  under-
stood. Cellular 
r e c e p t o r s  f o r 
DENV may impact infection dynamics 
and subsequent clinical disease severity. 
Dendritic cell (DC) subsets express 
the DC-specific intracellular adhesion 
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molecule (ICAM) 3-grabbing non-
integrin (DC-SIGN) allowing direct 
infection of DCs by a number of 
pathogens. DENV has four serotypes, 
all of which use DC-SIGN (CD209), a 
C-type lectin, to infect DCs.1 L-SIGN is 
largely expressed on endothelial cells in 
liver sinusoids.2 In cell culture, human 
DCs become susceptible to DENV 
infection following transfection with 
DC- or L-SIGN. Primary human DCs 
naturally expressing DC-SIGN as well 
as monocytic cell lines transfected with 
DC- or L-SIGN facilitate cellular infec-
tion, release and propagation of infec-
tious DENV virions.1 For this reason, 
DC-SIGN and L-SIGN are attractive 
for use in assays assessing cellular infec-
tion or prevention of infection. 
To better understand how cellular 
receptors may inf luence infection in 
the presence of pre-existing neutralizing 
antibodies (NAb’s), we studied pre-
illness serum samples from Thai sub-
jects who subsequently experienced 
infection with the DENV-1 serotype. 
A f luorescence-activated cell sorting 
(FACS)-based assay was used to explore 
neutralizing capabilities of pre-illness 
serum samples mixed with DENV in 
the presence of B cell lymphoblastoid 
Raji cells transfected with either DC- or 
L-SIGN receptors. Antibody neutral-
ization was performed by incubating 
serially diluted test and control patient 
sera with DENV in 96-well round-
bottomed culture plates for 30 min-
utes.3 Subsequent DENV infection was 
performed by adding serial dilutions of 
DC- and L-SIGN cells to the plates and 
incubating them overnight. This assay 
allowed us to quantify the antibody 
neutralizing capacity of infected patients 
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Astrocytomas are 
the most common 
primary tumor 
a f f e c t i n g  t h e 
adult CNS, with 
grade IV, known 
as Glioblastoma 
Multiforme 
(GBM),  be ing 
the most lethal 
(12 –15 month 
median survival).1 
Specific adjuvant therapies in various 
astrocytoma models have been applied 
by using flow cytometry to measure 
the number of DC and L-SIGN cells 
infected in the presence of their NAb’s. 
In total, we tested sera from 18 sub-
jects who became infected with dengue 
and experienced a spectrum of dengue 
disease severities (non-hospitalized 
dengue fever, hospitalized dengue 
fever, hospitalized dengue hemorrhagic 
fever). The anti-DENV NAb titer in 
the sera was determined by calculating 
the dilution of sera at which point 50% 
of the DENV input was neutralized. 
Titers were determined for each sample 
in the presence of DC- and L-SIGN 
cells. A third neutralizing antibody 
titer was determined using the gold-
standard plaque reduction neutralizing 
test (PRNT). The above experiments 
are being repeated in ongoing experi-
ments with pre-illness sera samples from 
subjects who experienced DENV-2, 
DENV-3, or DENV-4 infections. 
The FACS-based assay using DENV 
permissive cell lines transfected with 
L- and DC-SIGN cellular receptors 
may increase understanding of DENV-
cellular interactions and host NAb 
immune profiles. This is especially 
important for quickly and effectively 
measuring anti-DENV NAb’s of large 
numbers of sera from recipients of 
clinical trial DENV vaccines in order 
to measure their efficacy in stimulating 
host humoral immune responses. The 
classic PRNT requires four to seven 
days to complete, making it less prac-
tical for quickly generating results when 
compared to the FACS-based assays that 
takes two days to complete. 
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FIGURE: Neutralizing antibody (NAb) attachment to DENV blocks attachment to Fc-γ-R on monocytes, thereby 
blocking infection. The same may be true for DC- and L-SIGN lectin receptors expressed on dendritic cells (DCs).4
Brain Tumor Stem Cells Isolated from a RasB8 Transgenic  
Murine Model Provide a Working Stem Cell Model for Malignant Glioma 
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in the clinical setting.2,3 However, 
the development of effective targeted 
therapies for GBM is heavily dependent 
on the investigation of its pathogenesis 
via appropriate preclinical models 
that closely reproduce the clinical and 
histologic characteristics of human 
astrocytomas. 
Currently there is limited under-
standing of the relative contribution 
of particular glioma cells to overall 
tumor growth. Recent studies have 
demonstrated a small fraction of cells 
displaying features of primitive neural 
progenitor cells with tumor-initiating 
potential, termed glioma stem cells 
(GSCs).4 One current debate is that the 
glioma immunophenotype varies, thus 
additional markers for GSCs are needed 
to improve their isolation. One well 
accepted marker for GSCs is CD133, a 
cell surface marker expressed on progen-
itors of hematopoietic and endothelial 
cell lineages. GSCs sit at the forefront of 
the cancer stem cell hypothesis, which 
suggests that only a small fraction pos-
sesses the ability to self-renew and main-
tain the tumor, while most cells forego 
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these two abilities as they differentiate 
into cells that become the phenotypic 
signature of the neoplasm. Current 
treatments aim to debulk tumors but 
fail to target GSCs leading to treat-
ment failure, recurrence, and ultimately 
mortality. Detecting these keystone cells 
in GBMs will provide insight into the 
mechanism of tumorigenesis and aid in 
the development of more precise treat-
ment modalities.
We used an invasive mouse astrocy-
toma model generated by stem cell trans-
genesis of an activated 12V-Ha-RAS 
gene under regulation of the human glial 
fibrillary acidic protein promoter.5 This 
model allowed us to describe the prolif-
erative and tumorigenic characteristics 
of GSCs. Astrocytoma lines contained a 
significant proportion of CD133+ cells, 
the majority of which expressed CD44, 
a marker present on neural stem cells 
and human GBM cells. Furthermore, 
a subpopulation of lineage negative 
(CD133+/44-) cells represented ~3% of 
the tumor population. One requisite of 
detecting GSCs is that, when sorted and 
plated at a single cell density per well, the 
cell must have the capacity to generate 
free-floating clusters of clonally derived 
progeny, called tumorspheres, and its 
description is based on the phenomenon 
of neurosphere formation that occurs 
with non-cancerous neural stem cells. 
CD133+ cells demonstrated greater 
tumorsphere formation and self-renewal 
via secondary tumorsphere formation 
after disruption of primary spheres 
compared to CD133- cells. CD133- cells, 
however, divided more extensively in 
culture than CD133+ cells, supporting 
the notion that CD133+ GSCs prolif-
erate at a slower rate than differentiated 
CD133- cells. CD133+ cells also showed 
enhanced tumorigenicity in vivo com-
pared to CD133- cells isolated from the 
same tumor (Figure 2). 
Here we described a subset of tumor 
cells derived from a transgenic model 
that addressed which of the morphologi-
cally diverse tumor cells could maintain 
tumor initiation and survival. Three 
findings suggest that these CD133+ cells 
were GSCs: they (1) generated clusters of 
clonally derived cells resembling tumor-
spheres, (2) underwent self-renewal after 
tumorsphere dissociation, and (3) differ-
entiated to recapitulate the phenotype of 
the tumor from which they originated.6 
Because these GSCs must be targeted 
to eliminate the possibility of recur-
rence, our findings aid in the search to 
identify and isolate GSCs in the clinical 
setting. With a greater understanding of 
FIGURE 1: GSCs in malignant astrocytomas. GSCs comprise a fraction of tumor cells and are thought to arise 
from either neural stem cells or specific differentiated cells which revert to stem cells. GSCs have been shown to be 
resistant to chemo-radiation modalities and may be responsible for highly recurrent GBMs. [Setoguchi, T., Taga T., 
Kondo, T. 2004].
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FIGURE 2: A). FACS analysis revealed a population of CD133+ cells present in tumor lines of V12: Ha-ras-GFAP 
transgenic mice, in particular, a subpopulation of lineage negative CD133+ cells. B). Astrocytoma cells were stained 
with anti-CD133 monoclonal antibody and separated using Miltenyi Biotech anti-biotin beads and AutoMACS. Highly 
purified populations of CD133+ and CD133- cells were obtained (middle panel). Bottom panel shows that CD133+ 
cells gave rise to equivalent numbers of CD133- and CD133+ progeny after expansion in vitro while sorted CD133- cells 
remained CD133- (>90%). C). Formation of highly invasive intracranial astrocytomas by CD133+ tumor cells from 
V12:Ha-ras-GFAP transgenic mice. Mice injected with CD133- cells exhibited no tumor growth (top panel) while 5/5 
mice injected with CD133+ cells exhibited extensive growth of infiltrative tumor (bottom panel). 
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The animals were sacrificed 12 hours 
following LPS injection or 24–36 hours 
after CLP, and mesenteric arteries (MAs) 
were dissected. Mesenteric arteries 
excised from WT mice that were 
sacrificed 24–48 hours after CLP were 
then placed in organ chambers, exposed 
to phenylephrine (PE), an α1 agonist, 
and vascular reactivity studies were 
performed. Contractile responses were 
measured by the changes in isometric 
tension of the mesenteric rings using 
a digital force isometric transducer 
connected to a data acquisition system. 
GSC properties, including resistance to 
various chemo-radiation therapies, we 
will possess greater insight to develop 
novel therapies for effectively eradicating 
GBM. 
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S e p t i c  s h o c k 
induced 
morbid it y and 
mortality, which 
i s  a  r e su l t  o f 
cardiovascular 
c o l l a p s e  a n d 
multisystem 
organ failure, may 
be attributed to 
vasodilation and 
hypotension. This 
leads to impaired 
vasoregulation, 
microcirculatory dysfunction, shunting, 
and critical organ hypo-perfusion. 
Hydrogen sulf ide (H
2
S), previously 
known to be produced by cystathionine-
γ-lyase (CSE), and also known to be a 
toxic gas, has been identified as a gaseous 
transmitter, like nitrous oxide (NO), 
which promotes vasodilation.1 This 
is likely done by hyperpolarization of 
vascular smooth muscle. Plasma H
2
S 
levels are known to be elevated following 
CSE upregulation/activation in sepsis.2 
We tested the hypothesis that this 
excess in H
2
S production contributes 
to vasoplegia and capillary leak due to 
enhanced endothelial cell permeability, 
and subsequent organ hypoperfusion, 
microcirculatory failure, hypotension, 
and death. 
To do this, age matched wild type 
(WT) and CSE knockout (CSE-/-) 
mice were exposed to a septic stimulus 
[25mg/kg intraperitoneal LPS injection 
or Cecal Ligation Puncture (CLP) ]. 
Cystathionine-γ-Lyase: A Target for Septic Shock
Vasocontractile responses showed a 
markedly attenuated contractile response 
to PE  (WT CLP, Emax ~130.926% vs 
WT, Emax ~259.564%), with Emax 
measuring the maximum contractile 
response. In WT- CLP MAs the PE 
response was 50.44% compromised 
while totally preserved in CSE-/-. 
It was further found that there 
was no difference in response between 
CSE-/- and untreated WT mice in the 
CLP model. Phenylephrine responses 
(tension calibrated in mg units) were 
also attenuated in WT+LPS (LPS treated 
PE DOSE RESPONSE CURVE
FIGURE 1. Because the degree of hyporesponsiveness to PE was significantly less attenuated in CSE-/-+LPS (25.40% 
reduction) than in WT+LPS (55.60% reduction) as compared to their control counterparts, the findings supported our 
hypothesis that vascular hyporesponsiveness in sepsis is mediated by CSE-dependent H
2
S.
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FIGURE 2. CSE -/- mice are shown to be protected from vasoplegia and have increased survival in sepsis.
WT mice) compared to WT (n = 5, 
Emax ~308 mg vs Emax ~694 mg). 
In addition, there was attenuation of 
the depressor response in CSE-/-+LPS 
(LPS treated CSE-/-) as compared to 
CSE-/- control mice (n = 5, Emax~789.6 
vs Emax~1059).  
Cell-sensing impedance substrate 
(ECIS) technology, a highly sensitive 
method quantifying permeability, 
further demonstrated that exposure of 
human lung microvascular endothelial 
cells to pathophysiologic levels (1mM) 
of H
2
S (as seen in sepsis), caused a 
significant decrease in average barrier 
resistance (cell-cell and cell-matrix), 
but not at physiologic levels (100μM). 
In the first 96 hours of sepsis induction, 
mortality studies with CSE models of 
CSE-/- and WT mice demonstrated a 
60% survival benefit in CSE-/-.
In conclusion, genetic deletion 
of the H
2
S forming enzyme, CSE, 
protects mice from vasoplegia and 
vascular endothelial permeability and 
more importantly has survival benefits 
in sepsis. Accordingly, CSE inhibitors 
In Vivo Persistence of Redirected T Cells Transduced  
at Decreased Oxygen Concentrations
Adoptive T cell 
therapy (ACT) 
has emerged as 
a n  i mp or t a nt 
s t r a t e g y  t o 
med i a t e  a nt i -
tumor immunity. 
As demonstrated 
b y  n u m e r o u s 
clinical trials to 
treat malignancies 
such as melanoma, 
this promising 
therapeutic 
approach employs 
T cells redirected 
against a target 
tumor antigen via introduction of 
a chimeric antigen receptor (CAR) 
or an ectopic TCR. Importantly, 
G e n a  G o r a ,  M S I I , 
A d v i s o r s :  V a l e r i e 
Dardalhon, PhD, Institut 
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and Naomi Taylor, MD, 
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Moleculaire de Montpellier, 
Montpellier, France
successful ACT requires that the 
transduced lymphocytes expand, persist 
and function in vivo.1 It has been 
hypothesized that this therapeutic 
strategy is often compromised by the ex 
vivo transduction protocol. Specifically, 
to date, donor T cells have always been 
transduced at 20% oxygen, although 
physiological O
2
 concentrations in 
lymphoid organs range from 2–5%.2 
High oxygen concentrations could 
potentially alter multiple parameters 
including T cell differentiation, gene 
expression, as well as in vivo expansion 
and function. 
Here we address the above concerns 
by comparing the in vivo fate of cells 
transduced ex vivo under physiological 
(2%) and atmospheric (20%) oxygen 
conditions. Toward this goal, we 
engineered lymph-node (LN) T Cells 
from a congenic strain of donor mice 
(Thy1.1+) to express a CAR specific 
for the human CD19 antigen fused to 
a T-cell receptor CD3-zeta signaling 
chain.3 Expression of the CAR was done 
using mouse leukemia virus (MLV)-
mediated transduction in either 20% or 
2% oxygen culture conditions.  
To assess the in vivo eff icacy of 
ACT-mediated tumor prevention, host 
mice were injected subcutaneously 
with 4x105 mouse lymphoma cells 
(EL-4 cell line) expressing the huCD19 
antigen. On the same day, CAR-
transduced donor T Cells were labeled 
with Carboxyfluorescein succinimidyl 
ester (CFSE), a cytosolic dye used to 
may have therapeutic potential in sepsis 
therapy.
REFERENCES:
1. TANG C, LI X, DU J. (2006). Hydrogen sulf ide 
as a new endogenous gaseous transmitter in 
the cardiovascular system. Current vascular 
pharmacology, 4(1), 17–22.
2. HUI Y, DU J, TANG C, BIN G, JIANG H (2003). Changes in 
arterial hydrogen sulfide (H
2
S) content during 
septic shock and endotoxin shock in rats. J 
Infect., 47(2),155–60.
T CELLS Continued on p. 14
Fusion ✦ 201114
FIGURE 2: Phenotype of engrafted (Thy1.1+) donor cells recovered from hosts LN. Donor T cells were stimulated for 48 hours by anti-CD3/anti-CD28 mAbs, under either 
20% or 2% oxygen culture conditions. MLV-mediated transductions were performed on fibronectin-coated plates. (A) Gene transfer efficiency was assessed by monitoring huCD34 
gene expression-marker by FACS. (B) CD4 and CD8 expression of transduced (huCD34+) and non-transduced (huCD34-) recovered cells. (C) CD44 and CD62L expression of 
CD4+-gated cells on day seven post-transfer. 
monitor lymphocyte proliferation in 
vivo, and 7x106 cells were injected 
intravenously into host mice. Following 
ACT, tumor growth was assessed on 
days 10, 13, 17, and 21 and mice were 
sacrificed at days seven and 21. Lymph 
nodes and spleens were harvested and 
the cell suspensions were analyzed 
by f low cytometry. Factors assessed 
included transduction efficiency, donor 
T-cell survival, proliferation, and 
differentiation. 
We demonstrate that ex vivo gene 
transfer efficiency was comparable at 
2% and 20% O
2
 in engrafted donor 
cells recovered from hosts’ LNs (Figure 
2a). Donor huCD19-specific T cells 
transduced at both 2% and 20% 
O
2
 prevented tumor development as 
compared to hosts that received non-
transduced (NT) cells cultured at similar 
conditions (Figure 1). Interestingly, the 
phenotype of the redirected T cells was 
altered. Cells transduced at physiologic 
oxygen resulted in modified CD4:CD8 
ratios (Figure 2b), associated with 
a decreased proliferation (data not 
shown) and percentage of CD4+ T Cells 
with an effector phenotype (CD44+, 
CD62L-) (Figure 2c). While the overall 
persistence and dif ferentiation of 
the transduced cells was markedly 
modified by the oxygen concentration 
to which cells were exposed during the 
transduction period, it is notable that 
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these phenotypic differences had little 
effect on the recovery of transduced T 
cells following adoptive transfer into 
pre-conditioned mice (data not shown). 
Our studies demonstrate that 
oxygen concentration during ex vivo 
transduction protocols has a significant 
effect on transduced donor lymphocytes. 
These f indings can potentially be 
of therapeutic va lue in ACT for 
malignancies as transducing T cells 
at a more physiological concentration 
improve s  thei r  per s i s tence and 
functionality.
FIGURE 1: Adoptive transfer of CAR-transduced T cells specifically prevents tumor growth in lymphodepleted hosts. 
Prior to adoptive transfer, donor LN T-cells were transduced with a huCD19-specific CAR at 20% O2 (CAR 20%), 2% 
O2 (CAR 2%) or not transduced, but cultured under similar conditions at 20% O2 (NT 20%).
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In vivo Imaging of the Cannabinoid CB1 Receptor  
Using Positron Emission Tomography
The actions of 
marijuana (can-
nabis) are medi-
ated by receptors 
(pr imar i ly the 
cannabinoid CB
1
 
rec eptor)  t hat 
have unusually 
high density and 
wide distribution 
in the brain.1 In 
addition to medi-
ating the effects of 
exogenous drugs 
l i ke  c annabi s , 
these receptors also receive signals from 
endogenous cannabinoids (endocan-
nabinoids), which modulate the release 
of several other neurotransmitters. Since 
abnormalities of cannabinoid receptors 
and endocannabinoid transmission have 
been hypothesized to underlie disorders 
of the brain (e.g., memory impairment, 
schizophrenia, and seizures), this neu-
rotransmitter system has been an active 
target for development of drug therapies 
and of biomarkers to measure its in vivo 
function. Positron emission tomography 
(PET), which can image the distribution 
of receptors in the body, is a powerful 
tool for drug development, and can 
quantify the receptor as a biomarker to 
assess pathophysiology.2 The purpose of 
these studies was to evaluate several can-
didate PET radioligands for their relative 
ability to quantify CB
1
 receptors in the 
living brain of animals and humans. 
We first assessed [11C]MePPEP as 
a PET radioligand through studies in 
rodents.3 Wild-type and genetically 
modified mice were used to determine 
that [11C]MePPEP is not a substrate for 
the P-glycoprotein eff lux transporter 
and that the majority (about two-thirds) 
of its binding in brain is specific to the 
CB1 receptor. Pharmacologically active 
doses of CB
1
 agonists had no effect on 
[11C]MePPEP in rats, which suggests a 
large CB
1
 receptor reserve (Figure 1). 
Pharmacokinetic modeling of CB
1
 
receptors using brain radioactivity and 
measurements of radioligand in arterial 
plasma yielded stable measures after 
70 minutes of scanning. The results 
suggest that [11C]MePPEP might be suc-
cessful in humans, although competition 
studies with endocannabinoids would 
not be possible, and radiometabolites 
might cause consistent overestimation 
of CB
1
 receptor density. 
Second, we examined [11C]MePPEP 
in healthy human subjects using the 
“gold standard” of compartmental 
modeling to quantify receptor density 
in brain.4 [11C]MePPEP had high 
uptake in brain, could be imaged for 
210 minutes, and could quantify CB
1
 
receptors within about 60 minutes 
of scanning. However, the accuracy 
and precision of the pharmacokinetic 
modeling hinged upon the accuracy of 
radioligand measurements in arterial 
plasma. A radioligand with a longer 
radioactive half-life, such as from 18F, 
would be expected to provide superior 
measurements in arterial plasma. 
We  t hen  e v a lu a t e d  s e ve r a l 
18F-radiolabeled analogues of MePPEP 
in monkeys. [18F]FMPEP-d
2
 was selected 
for study in humans due to its superior 
uptake in brain compared to [18F]FEPEP, 
and reduced uptake of radioactivity in 
bone compared to [18F]FMPEP.5 In 
humans, [18F]FMPEP-d
2 
could image 
and quantify CB
1
 receptors with better 
accuracy and precision compared to 
that of [11C]MePPEP. As suspected, the 
accuracy in measuring radioligand in 
arterial plasma was the critical improve-
ment needed in the pharmacokinetic 
modeling. 
Finally, we examined the biodistribu-
tion and estimated the dose of radiation 
that would be received in human studies 
using [11C]MePPEP and [18F]FMPEP-d
2.
6 
Both radioligands had high uptake in 
the brain, liver, and lungs, and both had 
significant uptake of radioactivity in the 
bone marrow, but not in bone (Figure 
2). Regardless, both radioligands have 
an effective dose similar to that of other 
clinically used PET radioligands. 
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FIGURE 1: [11C]MePPEP can be displaced by antagonist, and not by agonist, in rodent brain. Drugs were 
administered IV to rats 40 min after [11C]MePPEP. Compared to the baseline curve (■) inverse agonist rimonabant 
(❍) displaced the majority of radioligand, whereas agonists anandamide (Δ), methanandamide (∇), CP 55,940 
(◊), URB597 (anandamide reuptake inhibitor, ×), and URB597 with anandamide (+) were unable to displace the 
radioligand.
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In conclusion, we have shown 
that both [11C]MePPEP and [18F]
FMPEP-d
2
 can quantify CB
1
 receptors 
in brain. However, [18F]FMPEP-d
2
 is 
superior to [11C]MePPEP because it has 
greater precision and accuracy. Thus, 
[18F]FMPEP-d
2
 is a promising PET 
radioligand to measure CB
1
 receptors 
in vivo, and can now be used to explore 
the role of this receptor in human health 
and disease.
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Spontaneous Uveitis in the Absence of IFN-g in Transgenic Mice  
Expressing a Retina-specific T cell Receptor
Experimental 
autoimmune 
uve it i s  (E AU ) 
s e r v e s  a s  a n 
animal model of 
human uveit is. 
I n  m i c e ,  t h e 
c l a s s ic a l  E AU 
model is induced 
by immunization 
w i t h  r e t i n a l 
antigens such as interphotoreceptor 
retinoid binding protein (IRBP) in 
complete Freund’s adjuvant and in 
many cases with injection of pertussis 
Neena  Pa s s i ,  MS I I 
Advisor: Reiko Horai, PhD, 
National Eye Institute
toxin as an additional adjuvant. A new 
transgenic mouse strain expressing a 
T cell receptor specific for IRBP
161-180
 
(IRBP TCR Tg) has recently been 
developed in our laboratory.1 The IRBP 
TCR Tg mouse spontaneously develops 
EAU-like ocular inf lammation with 
early onset, providing a useful model to 
study the basic mechanisms of uveitis. 
Interferon-gamma (IFN-g) and 
interleuken-17 (IL-17) are two major 
cytokines involved in T cell effector 
functions and autoimmunity. Our 
previous studies showed that systemic 
neutralization of IFN-g exacerbated 
EAU,2 and IFN-g deficient (GKO) mice 
developed EAU comparable to their 
wild-type counterparts.3 A more recent 
study showed increased production of 
IL-17 in lymph nodes and in uveitic eyes 
of GKO mice.4 These results suggest 
that IL-17-producing Th17 cells might 
serve as pathogenic effector cells in 
GKO mice. 
In this study, to further investigate 
the roles of IFN-g and IL-17 in the 
development of uveitis, we sought 
to eva luate the development of 
spontaneous uveitis in the absence 
of IFN-g. GKO mice were crossed 
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FIGURE 1: IRBP TCR Tg-GKO mice spontaneously develop EAU-like uveitis with less severity than IRBP TCR Tg mice. 
Left, EAU scores of wild-type (Non-Tg), IRBP TCR Tg (Tg-Gwt), IRBP TCR Tg-GHet and IRBP TCR Tg-GKO mice between 
four and seven months old determined by histopathology. Scores were assigned on a scale of 0 to 4, according to 
the extent of inflammation and tissue damage. Each point represents one mouse (average of both eyes). (p<0.05). 
Right, Kinetics of disease onset in Tg-Gwt, Tg-GHet and Tg-GKO mice based on weekly fundoscopy readings. Tg-GKO 
mice showed similar disease incidence as their heterozygous and wild-type counterparts.
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FIGURE 2: TCR Tg-GKO mice produce IL-17. Culture supernatants of lymph node cells and splenocytes were 
stimulated with IRBP peptide (1μg/mL) were collected and measured for IFN-g (left) and IL-17 (right) by ELISA. 
Tg-GKO cells produced no detectable IFN-g as expected, whereas parallel supernatants for the other TCR Tg genotypes 
contained significant amounts of IFN-g. There was no significant difference in the amount of IFN-g produced by Tg-Gwt 
and Tg-GHet mice. Measurements of IL-17 in the same supernatants showed that Tg-GKO mice produced more IL-17 
than the wild-type controls and Tg-GHet mice; however, these differences were not statistically significant. 
with the IRBP TCR Tg mice and 
their disease progression and cellular 
responses were examined. Fundospic 
and histopathologic analysis were 
used to monitor retinal inflammation 
and disease progression. IRBP
161-180
-
specific lymphocyte proliferation was 
assessed with [3H]-Thymidine staining. 
IFN-g and IL-17 production in culture 
supernatants were analyzed by ELISA. 
Our study revealed that IRBP TCR 
Tg-GKO mice develop spontaneous 
uveitis with similar incidence, but 
less severity than their heterozygous 
(IRBP TCR Tg-GHet) and wild-
type (IRBP TCR Tg) littermates, 
suggesting that IFN-g is dispensable 
for disease onset but may have a role in 
disease progression (Figure 1). Lymph 
node cells and splenocytes from the 
IRBP TCR Tg GKO mice exhibited 
comparable proliferation responses to 
IRBP
161-180
 as compared to their wild 
type controls, supporting previous 
findings that IFN-g is not required for 
priming pathogenic T cells (Figure not 
shown). Lymphocytes from IRBP TCR 
Tg-GKO mice produced more IL-17 
than those from the IRBP TCR Tg 
mice, suggesting that IL-17-producing T 
cells may play a role in the development 
of uveitis in IRBP TCR Tg-GKO mice 
(Figure 2). Further studies are needed to 
elucidate the roles of IFN-g and IL-17 in 
the development of autoimmune uvietis. 
REFERENCES:
1. HORAI R, AND CASPI R. Laboratory of Immunology, 
National Eye Institute, National Institutes of 
Health, NIH.
2. CASPI R, CHAN C, GRUBBS B, SILVER P. WIGGERT B, PARSA 
CF, ET AL. (1994). Endogenous systemic IFN-
gamma has a protective role against ocular 
autoimmunity in mice. J. Immunol. 152: 
890–899.
3. JONES L, RIZZO L, AGARWAL R, TARRANT T, CHI-CHAN C, 
WIGGERT B, AND CASPI R. (1997). IFN-γ-Deficient 
Mice Develop Experimental Autoimmune 
Uveitis in the Context of a Deviant Effector 
Response. J. Immunol. 158: 5997–6005.
4. LUGER D, SILVER PB, TANG J, CUA D, CHEN Z, IWAKURA Y, 
ET AL. (2008). Either a Th17 or a Th1 effector 
response can drive autoimmunity: conditions 
of disease induction affect dominant effector 
category. J Exp Med. 205: 799–810.
!
WT
Tg-
Gw
t
Tg-
GH
et
Tg-
GKO
5,000
4,000
3,000
2,000
1,000
0IFN
-γ 
(p
g/
ml
)
ELISA IFN-γ (Spleen)
WT
Tg-
Gw
t
Tg-
GH
et
Tg-
GKO
0
500
1,000
1,500
IL-
17
 
(p
g/
ml
) ELISA IL-17 (Spleen)
WT
Tg-
Gw
t
Tg-
GH
et
Tg-
GKO
5,000
4,000
3,000
2,000
1,000
0IFN
-γ 
(p
g/
ml
)
ELISA IFN-γ (LN)
1,500
1,000
0
500
IFN
-γ 
(p
g/
ml
)
WT
Tg-
Gw
t
Tg-
GH
et
Tg-
GKO
WT Tg-Gwt Tg-GHet Tg-GKO
ELISA IL-17 (LN)
Fusion ✦ 201118
 clinical practice
Thoracic aortic 
surgery, with or 
w i t hou t  d e e p 
hypothermic 
a r r e s t ,  i s  a n 
inherently 
precarious 
cardiac operation 
characterized 
by aberrat ions 
in the norma l 
p r o p e r t i e s  o f 
blood. These alterations in hemostasis 
and thrombogenesis are associated with 
particularly increased rates of stroke 
and mortality, and consequently, there 
is a need to finely control postoperative 
bleeding in this subset of surgeries.1,2 
The safety of aprotinin use in cardiac 
surgery has been heavily debated, 
both before and after its withdrawal 
by the FDA in 2007. Concerns have 
centered on putative excess thrombosis, 
embolism, and renal failure.3,4,5,6 A pilot 
study at our institution suggested that 
in thoracic aortic surgery, aprotinin, an 
antifibrinolytic serine protease inhibitor, 
was safe and effective for conventional 
use in these operations.7 The aim of 
this investigation was to determine if 
a larger cohort would confirm safety 
and efficacy of aprotinin in thoracic 
aortic surgery. In this case-control 
study, we demonstrate that the use 
of aprotinin offers all benefit and no 
liability in thoracic aortic surgery. 
Patients undergoing surgery for thoracic 
aneurysm or dissection at Yale-New 
Haven Hospital between 1995 and 
2010 were considered for inclusion 
in this study. 183 patients receiving 
aprotinin during this time period 
were each matched with 183 controls 
based on preoperative criteria (age, 
gender, urgency of surgery, location of 
aneurysm) for a total enrollment of 366 
patients. Pre- and post-operative data 
were collected from the medical records 
of aprotinin patients and their matched 
controls. Success of matching was 
assessed by bivariate analysis and then 
clinical outcomes analyzed. Among 
t he  36 6  subje c t s 
enrolled in this study, 
aprot inin pat ients 
showed signif icant 
benefits compared to 
controls in 24-hour 
chest tube drainage, 
RBC transfusion, platelet transfusion, 
and total ventilation time (see figure). 
There were three cases of renal failure 
in aprotinin patients and one in controls 
while there were also seven embolic 
events in aprotinin patients and seven in 
the controls. There were no Myocardial 
Infarctions (MI) in the aprotinin 
patients and three in the controls. 
Additionally, (in paired analysis for 
d ichotomous c l inica l  outcomes) 
aprotinin patients showed an odds 
ratio of 0.48 (p-value 0.02) for any 
complication (embolism, MI, stroke, 
renal failure, pulmonary complication, 
arrhythmia, or death). Our findings 
demonstrate that clinical outcomes 
and complications were significantly 
reduced in patients receiving aprotinin 
as compared to those that did not. The 
results of this study lead us to believe 
that aortic surgery and aprotinin may 
be especially suited to each other. We 
simply did not f ind the purported 
deleterious effects associated with this 
drug. Thoracic aortic surgical patients 
 Outcomes Aprotinin (n=183)  Control (n=183)  P-value 
 24 Hr Drainage 590.4¬±290.9 763.4¬±470.8  0.0001*
 RBC transfusion 1.84¬±2.36  2.5¬±2.97  0.01*
 FFP transfusion 1.75¬±2.36  2.26¬±3.64  0.11 
 Platelet transfusion 0.78¬±1.36  1.54¬±2.07  0.0001* 
 Total ventilation (min) 1403¬±1834 1992¬±3210  0.03* 
FIGURE: Unpaired analysis for continuous clinical variables.
* denotes statistical significance 
Appropriate Role of Aprotinin in Thoracic Aortic Surgery: Should We Have it Back?
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The results of this study lead us to believe 
that aortic surgery and aprotinin may be 
especially suited to each other.
are likely suffering from aprotinin 
withdrawal, and its reinstatement 
for this specific indication should be 
considered.
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We  r e p o r t  a 
ca se of a man 
i n  h i s  for t i e s 
presenting with 
radiating leg pain. 
Radiculopathy 
was d iagnosed 
by  a  pre v iou s 
physician based 
o n  M a g n e t i c 
Resonance 
Imaging (MRI) 
f indings and physical examination. 
Epidural injections were ineffective in 
relieving pain. Upon referral to this 
practice, an ultrasound examination 
demonstrated a large sacral bursa 
compressing the sciatic nerve, which was 
not apparent on pelvic MRI. This bursa 
was drained and injected with cortisone, 
resulting in pain resolution.
The United States Agency for Health 
Care Research and Quality guideline 
specifies MRI as the modality of choice 
for suspected spinal soft tissue damage, 
such as radiculopathy.1 A review article 
on lumbosacral radiculopathy states 
that diagnosis should be confirmed with 
MRI or electromyography (EMG).2 If 
a disc herniation is found, it should be 
treated with a pain treatment plan or an 
Use of Musculoskeletal Ultrasound to Diagnose  
and Treat Symptomatic Sacral Bursitis: a Case Report
Matthew Bean, MSIII 
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epidural injection. For pain refractory 
to treatment after four weeks, surgical 
evaluation is indicated.2
Bursitis has been shown to mimic 
lumbosacral radiculopathy at multiple 
locations including the piriformis 
bursa,3 trochanteric bursa,5 and iliopsoas 
bursa.4 Swezey et al suggests that this is 
common in an elderly population, with 
thirty-one out of seventy patients having 
bursitis versus radiculitis. 
In the United States, MRI is the 
imaging study of choice for diagnosis of 
bursitis.7,8 Ultrasound 
has also been shown 
to be ef fect ive in 
diagnosis of bursitis 
compared with MRI 
but less detailed.6,9 In 
Europe, ultrasound is 
the study of choice for 
the identification of 
iliopsoas bursitis due to its lower cost 
versus MRI.9 
To our knowledge, this is the first 
case reported in the literature where MRI 
failed to identify bursitis. As morbidity, 
mortality, and cost associated with 
surgery are high, it may be reasonable 
to rule out bursitis prior to proceeding 
with surgical intervention. In addition, 
due to the lower cost and in this case 
report greater accuracy, ultrasound may 
be preferable over MRI as an initial 
diagnostic modality for bursitis as is 
done in Europe.
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Due to its typical 
l a t e  c l i n i c a l 
presentation 
and aggressive 
c o u r s e ,  l u n g 
cancer continues 
to be the leading 
cause of cancer 
mortality 
worldwide. 
Lobectomy has 
been established 
as the primary curative option for 
early-stage non-small cell lung cancer 
(NSCLC) with f ive-year overa l l 
survival rates between 60–80% and 
loca l control rates ranging from 
5–11%, based on historical data.1 
Nonetheless, many newly diagnosed 
patients are older with multiple medical 
co-morbidities, precluding them from 
surgical management. Prior studies have 
attempted to establish external beam 
of these studies, RTOG standard 
margins were adopted for the clinical 
treatment volume, which includes 
1.0 cm longitudinally and 0.5 cm 
axially. Our study aims to narrow these 
margins and thus decrease normal 
lung tissue damage, measured by 
the volume receiving 
15 Gray (V15), while 
ma inta ining loca l 
control and overall 
survival rates.
Inoperable patients 
with biopsy-proven 
periphera l cl inica l 
stage IA NSCLC were 
enrolled in this single institution study. 
Three to five gold fiducial markers were 
implanted in or near tumors under 
computed tomography (CT) guidance 
to serve as targeting references. Gross 
tumor volumes (GTVs) were contoured 
using lung windows and margins were 
expanded 5 mm circumferentially to 
establish the planning treatment volume 
(PTV). Non-isocentric treatment 
plans were designed using hundreds of 
pencil beams with a median collimator 
diameter of 25 mm. All treatments 
were delivered utilizing the CyberKnife 
system with Synchrony. Gross tumor 
doses ranged from 42–60 Gray (Gy) in 
three equal fractions (BED Gy10 >100).4 
Clinical examination and PET/CT 
imaging were completed at six-month 
intervals following treatment. The V15 
was calculated using standard RTOG 
margins and 5 mm margins (Figure 1).
Twenty-four patients with a mean 
maximum tumor diameter of 2.2-cm and 
a mean GTV of 10 cc were treated over 
a four-year period. The mean calculated 
V15 was 202 cc with a 5 mm margin 
and 236 cc with the RTOG margins. 
At a mean follow-up of 36 months, the 
three-year Kaplan-Meier local control 
and overall survival estimates were 
95% and 79%, respectively (Figure 2). 
Five patients with severe emphysema 
(baseline post-bronchodilator FEV
1
 < 
40% predicted) died of progressive lung 
dysfunction following treatment.
Robotic radiosurgery with image 
guidance offers a precise and effective 
treatment for inoperable peripheral 
stage IA NSCLC. Limiting the margin 
to 5 mm decreased the V15 by an 
average of 35 cc (range, 15–60 cc) 
while preserving local control rates 
comparable to published studies using 
larger margins.3,4 The ability to spare 
lung tissue is of great importance since 
Robotic Radiosurgery for Inoperable Patients with Peripheral Stage IA  
Non-Small Cell Lung Cancer: Local Control and Survival Using 5-mm Margins
FIGURE 1: CyberKnife treatment planning  with RTOG standard margins (left) and 5 mm margins (right). 
The V15 is 76 cc and 53 cc, respectively.
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Robotic radiosurgery with image guidance 
offers a precise and effective treatment for 
inoperable peripheral stage IA non-small cell 
lung cancer. 
radiotherapy as a treatment modality 
in early-stage, medically inoperable 
NSCLC; however, survival rates and 
toxicity associated with such treatment 
have been discouraging.1
The relatively new technique of 
stereotactic body radiotherapy (SBRT) 
enables the delivery of high doses in 
few fractions. Several studies have now 
been conducted, providing evidence 
of excellent local control rates and 
improved overall survival with SBRT; 
toxicity remains a concern, however, 
due to normal lung tissue exposure 
to radiation.2–4 Of note, in a majority 
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FIGURE: Washington, D.C., Metropolitan Area Distribution of Acute Chest Syndrome Episodes in Sickle Cell Disease 
Patients by Socioeconomic Status.
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Washington, D.C., Metropolitan Area Distribution of Acute Chest Syndrome Episodes
in Sickle Cell Disease Patients by Socioeconomic Status
progressive lung dysfunction was the 
sole cause of death among this group 
of patients. 
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Demographics of Pulmonary Complications in Sickle Cell Disease
Sickle cell dis-
ease (SCD) is an 
inherited blood 
d i s o rd e r  t h a t 
affects multiple 
organ systems, 
with both acute 
a n d  c h r o n i c 
manifestations. 
Pulmonary com-
plications are of 
particular impor-
tance in patients 
w i t h  S C D  a s 
they a re com-
monly associated 
with high morbidity and mortality.1,2 
Research suggests that children with 
both SCD and asthma have higher mor-
bidity as measured by more frequent hos-
pitalizations for vaso-occlusive crises and 
acute chest syndrome (ACS) episodes, 
and as much as double the risk of mor-
tality when compared to pediatric SCD 
patients without asthma.3 Therefore, the 
diagnosis of reactive airway disease in 
pediatric SCD patients is clearly a poor 
prognostic factor. However, it is currently 
not known whether there is any degree of 
modifiable risk associated with aggressive 
empirical treatment of asthma in the 
pediatric SCD population. Although 
SCD disproportionately affects people of 
African and Latino ancestry, the associa-
tion between socioeconomic status and 
prevalence of SCD is unknown. 
This study investigated whether 
socioeconomic status, as determined by 
zip code distribution in the Washington 
Metropolitan Area, correlates with reac-
tive airway disease in pediatric SCD 
patients as it does in asthmatic children 
without SCD. A five-year retrospective 
study examined randomly sampled 400 
out of 950 total pediatric SCD patients 
seen at Children’s National Medical 
Center between 2008 and 2010. We 
extracted hematological, pulmonary as 
well as demographic patient informa-
tion from electronic medical records 
(Cerner PowerChart system). Median 
household incomes from 2008 were 
linked to zip codes in various regions 
of the Washington Metropolitan Area 
and results were then analyzed using 
non-parametric statistical methods. The 
Mann Whitney U test was used to deter-
mine differences in the characteristics 
between pediatric SCD patients with 
a diagnosis of reactive airway disease 
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FIGURE 1:Scatter plots for blood pressure versus Metabolic Equivalents (METs) achieved. 
Solid black circle = systolic blood pressure, Hollow circle = diastolic blood pressure.
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versus those without a diagnosis of reac-
tive airway disease. 
Among the 400 pediatric SCD 
patients, there was a strong inverse rela-
tionship between socioeconomic status 
and the rate of acute chest syndrome 
episodes (mean number of episodes 
per patient per year). The rate of acute 
chest syndrome episodes was 0.20 for 
all of Washington DC (n=56), 0.15 for 
Prince George’s County (n=147), 0.10 
for Montgomery County (n=81), and 
0.04 for Fairfax County (n=33), which 
had median household incomes of $58k, 
$72k, $94k, and $107k, respectively. 
Acute chest syndrome episodes were 
also significantly more prevalent in 
children diagnosed with reactive airway 
disease (18.75%) compared to those with 
no history of asthma (p < 0.05). 
Socioeconomic status as marked by 
geographical distribution appears to be a 
strong source of diversity in pulmonary 
complications of pediatric SCD patients 
in the Washington Metropolitan Area. 
Our data is subject to the limitations 
of a retrospective chart review, but it 
effectively sets the stage for future pro-
spective studies. Also, further analysis of 
this data could account for differences 
in the rate of acute chest syndrome epi-
sodes in SCD patients on hydroxyurea 
or chronic transfusions, as opposed to 
those not undergoing any treatment 
for SCD. Lastly, the data can be useful 
in planning service delivery, such as 
evaluating whether a satellite pulmo-
nary-hematology clinic might enhance 
convenience of service for pediatric 
SCD patients in the Washington, D.C., 
Metropolitan Area. 
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Flat Blood Pressure Response to Exercise in Patients  
with the Total Artificial Heart: The Feasibility of Cardiac Rehabilitation
The total artificial 
heart (TAH) is 
a  me c h a n i c a l 
circulatory 
support 
d e v i c e  t h a t 
orthotopically 
r e p l a c e s  a 
recipient’s native 
vent r ic le s  and 
all four cardiac 
valves (Figure 2). 
To t a l  h e a r t 
replacement is an 
effective bridge to transplant for patients 
with bi-ventricular heart failure and 
is an alternative to implantation of 
concomitant right and left ventricular 
assist devices. The TAH consists of 
two implantable pneumatic pumps 
operating at a fixed ejection rate and 
ejection pressure.1 Increases in cardiac 
output during activity with TAH are 
thought to be dependent on increased 
venous return. The blood pressure 
(BP) response to and safety of exercise 
in patients with a TAH have not been 
reported. We hypothesized that blood 
pressure does not augment in response 
to exercise in patients with a TAH. 
Here we show that during circulatory 
support with a TAH, there was a flat BP 
response to exercise, meaning BP did 
not significantly increase or decrease. 
However, aerobic exercise training early 
after device implant was safe and feasible 
in a supervised setting. In this study, 
30 patients participated in physical 
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negatively correlated with 
METs achieved during exer-
cise and the association was 
not statistically significantly 
(systolic: β = -0.09, p = 0.3, dia-
stolic: β = -0.14, p = 0.2) (Figure 
1). The maintenance of 
systemic blood pressure 
with activity is 
possibly related 
to increased 
venous 
return 
(preload), 
which in turn 
increa ses the 
stroke volume of 
the right and left TAH 
pumps. Venous return 
during exercise is facili-
tated by the skeletal muscle 
contraction, neurally mediated veno-
contraction and respiratory pumps.2,3,4 
Additionally, concom-
itant regional vaso-
constriction in the 
splanchnic and renal 
beds helps maintain 
and augment systemic 
blood pressure during 
exercise.5
This study demon-
strates that patients with a TAH (1) have 
a flat blood pressure response to exercise, 
(2) can safely participate in a physical 
rehabilitation program early after device 
implantation, and (3) exhibit improve-
ment in exercise performance over the 
course of a rehabilitation program. 
These are the first data to describe the 
safety, implementation and efficacy of 
therapy and 22 of these patients 
proceeded to participate 
in treadmill rehabilita-
tion. After TAH implant, 
patients initiated physical 
therapy at a median of five 
days (IQR: four – seven days) 
and 22 patients began 
treadmill exercise 
at a median of 
19 days (IQR: 
13 – 35 days). 
The duration 
of  t readmi l l 
exercise (week 
1:  8.35 ± 3.29 
minutes vs. week 4: 
18.62 ± 9.07 minutes, 
p < 0.001; week 1: 8.70 
± 3.80 minutes vs. week 
8: 25.95 ± 15.06 min-
utes, p = 0.006) and the Metabolic 
Equivalents (METs)6 achieved increased 
a regimented physical rehabilitation 
program for patients supported with an 
artificial heart.
Currently in the United States, 
patients with a TAH are bound to 
inpatient wards of hospitals, as the 
size and weight of the device prohibit 
patient discharge. However, utilization 
of a portable console is currently under 
investigation. The results of this study 
are pertinent as patient rehabilitation 
and mobility will be of increasing con-
cern as TAH patients will be free to go 
home in the near future. Future patient 
studies measuring multiple exercise 
metrics with more intense exercise in a 
prospective manner will provide further 
guidance on rehabilitation for patients 
with the device.
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FIGURE 2: Total artificial heart 
(courtesy of www.syncardia.com). 
The results of this study are pertinent as 
patient rehabilitation and mobility will be 
of increasing concern as TAH patients will 
be free to go home in the near future. 
over the course of rehabilitation (week 
1: 1.53 ± 0.13 METs vs. week 4: 1.85 
± 0.24 METs, p < 0.001; week 1: 1.53 
± 0.13 METs vs. week 8: 2.30 ± 0.52 
METs, p = 0.001). The BP’s before, 
during and post-exercise were similar 
(120/69 ± 13/13 vs. 118/72 ± 15/10 vs. 
120/72 ± 14/12 mmHg; systolic: p = 
0.3, diastolic: p = 0.1). The BP’s weakly 
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Cerebral venous 
sinus thrombosis 
(CVST) is a rare 
but life threat-
ening disorder in 
children that has 
been more readily 
d iagnosed and 
managed due to 
enhanced neuro-
imaging modali-
t ie s ,  improved 
identification of 
risk factors, and 
increa sed cov-
erage in the literature. Some risk factors 
include head or neck infections, acute 
systemic illness, hematologic disorders 
and prothrombotic states including 
homocysteinemia.1–2 Multiple studies 
have shown that the most common sites 
for thrombosis were the superior sagittal 
sinus (55%), lateral or transverse sinuses 
(51%), and the straight sinus (24%).1 Of 
the numerous presentations of throm-
bosis, headache is reported in 90% 
of cases.2 Following clinical suspicion 
of sinus thrombosis, MRI and MRV 
(Magnetic Resonance Venography) are 
the gold standard diagnostic tools.2 
After the diagnosis has been established, 
the majority of existing data supports 
systemic anticoagulation as the initial 
step in treatment. Patients with more 
serious presentations or those with 
clinical deterioration require direct 
thrombolysis or surgical intervention 
and anticoagulation.3–5 Anticoagulation 
is typically achieved with heparin and 
this is the medication of choice for the 
majority of stable patients.6 
Our case highlights a 14-year-old 
right-hand-dominant female that pre-
sented for evaluation of a cerebellar 
lesion. She had a recent history of 
headache and vomiting and positive 
dysmetria in her right upper extremity 
on exam. Past medical history was 
pertinent for premature birth and 
colectomy secondary to necrotizing 
enterocolitis. Upon admission, she was 
noted to have a decline in mental status. 
The patient was initially following com-
mands but this func-
tion diminished soon 
thereafter. A head CT 
showed a large right 
cerebellar hemisphere 
infarct with right-to-
left shift and tonsillar 
herniation secondary 
to mass effect from 
the infarct. Right sub-
occipital craniotomy 
with right cerebellar 
partial lobectomy of necrotic brain with 
placement of a twist drill right frontal 
ventriculostomy was performed by 
neurosurgery. No complications from 
surgery were observed upon discharge. 
The patient was sent home on colace, 
enoxaparin, glycerin suppository, and 
vitamin B complex therapy. She pre-
sented at follow-up without complaints 
of headache, nausea, vomiting or other 
complications. Subsequent evaluation 
showed elevated homocysteine levels. 
This case illustrates the most evi-
denced-based management for a patient 
with suspected venous sinus thrombosis. 
The patient’s history of infantile gastro-
intestinal disease and homocysteinemia 
are known risk factors for CVST.2,9 
Exam findings including headache and 
vomiting prompted ordering a brain CT, 
a valid initial imaging tool for cerebral 
venous sinus thrombosis.7 Interestingly, 
the team caring for this patient decided 
to use enoxaparin prophylaxis after 
surgery. Although enoxaparin is more 
expensive than heparin, its once daily 
dosing, and lower heparin induced 
thrombocytopenia risk for patients with 
good renal function made it a better 
option in this case. Based on a literature 
review and the outcome of our case, diag-
nosis and treatment of CVST remains 
very difficult due to rarity of cases and 
clinical variability.8–9 Further research 
must be undertaken to determine the 
effectiveness of treatment choices such as 
enoxaparin as the best possible manage-
ment for these patients.
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FIGURE 1A: Pre-Treatment. MR Venogram consistent 
with thrombosis of the straight, right transverse, sigmoid 
dural venous sinuses, the vein of Galen, and the internal 
stable veins and the basal veins of Rosenthal as well as 
the inferior sagittal sinus.
FIGURE 1B: Post-Treatment. There has been interval 
partial recanalization of the right sigmoid, transverse 
sinuses. There is also questionable minimal signal in the 
vein of Galen with persistent thrombosis of the straight 
sinus and the internal cerebral veins.
Although enoxaparin is more expensive than 
heparin, its once daily dosing, and lower 
heparin induced thrombocytopenia risk for 
patients with good renal function made it a 
better option in this case.
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CyberKnife Radiosurgery for Previously Irradiated Vaginal Tumors
Vagina l recur-
rences and the 
subsequent devel-
opment of meta-
static disease is 
a  we l l  k now n 
pattern of gyne-
colog ica l  c an-
cers. Therefore, 
the primary goal 
of initial radio-
therapy should be 
to prevent these 
vaginal failures. 
Patients presenting with primary 
and recurrent vaginal tumors have 
historically been successfully treated 
with several weeks of conventionally 
fractionated radiation therapy followed 
by several days of inpatient low-dose 
rate (LDR) intracavitary or interstitial 
brachytherapy. To improve patient 
tolerance of the therapy, researchers in 
the past decade have developed effec-
tive outpatient high-dose rate (HDR) 
brachytherapy protocols.5 
Regardless of the method, brachy-
therapy is an invasive procedure associ-
ated with physical and psychological 
discomfort and anxiety1-4 and chronic 
bowel, bladder and vaginal toxicity. 
The current standard treatment for 
primary or recurrent vaginal carcinoma 
usually involves external beam radiation 
therapy (EBRT) and/or brachytherapy 
(BT).5 EBRT generally decreases the 
initial tumor size, and BT is used sub-
sequently. BT is used for a small cancer 
volume (i.e. less than 3 to 4 cm in 
diameter) and requires inserting a radio-
active source (or radioisotopes) directly 
into or around the cancer. The highest 
radiation doses are delivered closest to 
the radioactive source. BT may be either 
intracavitary (sealed radioactive source 
within a body cavity, i.e. the vagina) or 
interstitial BT, a procedure that delivers 
radiation using needles inserted into the 
cancer and the surrounding tissues prior 
to salvage therapy.6 
The CyberKnife is a novel mini-
mally invasive means of delivering 
brachytherapy-like radiation dose distri-
butions to vaginal tumors (Figure 1). We 
report the clinical efficacy and toxicity 
of salvage CyberKnife radiosurgery 
for six patients with previously irradi-
ated vaginal tumors not amenable to 
brachytherapy. 
Six consecutive women were treated 
over a five-year period (Table 1). Two 
patients presented with primary vaginal 
tumors (vaginal squamous cell carci-
noma and urethral adenocarcinoma) 
and four with vaginal recurrences 
(uterine endometriod adenocarcinoma 
three and ovarian papillary serous 
carcinoma). We found that four of the 
six patients receiving > 30 Grays (Gy) 
with the CyberKnife procedure had 
a complete clinical response at three 
months post-therapy. Cancers found in 
two different patients (a primary vaginal 
adenocarcinoma and a recurrent papil-
lary serous uterine cancer) persisted at 
three months and ultimately progressed 
despite receiving 25 Gy of radiation. At a 
median follow-up of 23 months, the two-
year Kaplan-Meier local control of tumor 
growth and overall survival estimates 
were 56% and 100%, respectively. No 
severe (> grade 3) toxicities, defined as 
late gastrointestinal complications, life-
threatening complications, or complica-
tions requiring surgery,8 were attributed 
to CyberKnife treatment.7
Our results demonstrate that patients 
with vaginal tumors, which were previ-
ously unresponsive to conventional 
radiotherapy, may be successfully treated 
with the CyberKnife radiosurgery 
system. Further studies are needed to 
investigate this novel therapy among 
newly diagnosed patients. We believe 
such studies may adapt the current 
radiation treatment regimen of primary 
CYBERKNIFE Continued on p. 26
 Patient Age Performance Symptom Primary Histology GTV (cc) 
   Status (ECOG)   Cancer  
 1 45 0 Bleeding Uterine Papillary serous 18.56
 2 89 2 Bleeding Uterine Adenocarcinoma 43.24
 3 57 0 Bleeding Uterine Adenocarcinoma 52.48
 4 65 2 Dysuria Urethral Adenocarcinoma 14.35
 5 68 0 Bleeding Uterine Adenocarcinoma 80.83
 6 56 0 Dysuria Vaginal Squamous cell 44.46
TABLE 1: Patient and Tumor Characteristics
GTV = Gross Tumor Volume; ECOG = Eastern Cooperative Oncology Group Performance Status reflects effect 
of disease on patient’s daily life.9
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Bi-Rads Subcategorization as a Useful Predictor of Malignancy
In the late 1980s, 
t he  A mer ic a n 
C o l l e g e  o f 
Radiology 
( AC R )  b e g a n 
a n  i n i t i a t i v e 
t o  c r e a t e  t he 
Breast Imaging 
Report ing and 
D a t a  S y s t e m 
(BI-RADS) 
l e x i c o n  f o r 
mammography 
interpretation in order to standardize 
how to classify breast lesions and 
quantify their likelihood of being 
cancerous. Despite acceptance of this 
lexicon, interobserver variability was 
still high regarding the specific lesion 
classifications.
In 2003, the ACR further clarified 
each lesion by providing illustrations 
and representative photographs of each 
Ke r r i  V in cen t i ,  MSI 
Advisors: Laura Liberman, 
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and recurrent vaginal tumors to include 
CyberKnife as a first line treatment 
modality. 
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FIGURE 1: The CyberKnife LINAC is mounted on a robotic arm with six joints. One of the flat-panel amorphous 
silicon detectors can be seen on the side of the treatment table. (Courtesy of Accuray.com)
example. In addition to introducing a 
lexicon for sonography and MRI, the 
latest BI-RADS also further organized 
the category 4 lesions in three subgroups 
— 4a, 4b, and 4c.1 Lazarus et al. and 
Sanders et al. conducted retrospective 
studies of these subcategories focusing 
on microcalcif ications which both 
showed that the subcategories were 
useful predictors of malignancy.
One of the goals of this study was 
to look at the positive predictive value 
(PPV) of each subgroup to determine 
whether there is statistically significant 
correlation between the categories and 
the occurrence of cancer for masses. This 
HIPAA compliant and IRB approved 
retrospective study reviewed reports of 
73,760 mammograms at the New York 
Memorial Sloan-Kettering facility from 
Dec. 1, 2003–April 30, 2007 to identify 
all lesions referred for biopsy (n=1575). 
Patients were 23–95 years old at the 
time of their diagnostic mammogram 
(mean age 56.9 [± 13.3 years]). In all 
cases, a core needle biopsy, stereotactic 
core needle biopsy, or f ine needle 
aspiration was performed to determine 
pathology for the presence or absence 
of malignancy. Synchronous suspicious 
lesions (n = 261) were excluded to rule 
out multiple findings with different 
levels of suspicion. Film mammographic 
examinations were performed at either 
the Guttman Diagnostic Center or the 
Breast Examination Center of Harlem. 
Diagnostic evaluation included lateral 
and magnification views for all patients 
included in the study. Final assessment 
categories were independently assigned 
to each mammogram by one of five 
interpreting radiologists as follows: 
BI-RADS category 4a for lesions with 
low likelihood of malignancy; category 
4b for lesions with an intermediate 
likelihood of malignancy; category 4c 
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T he  Nat iona l 
C o u n c i l  o n 
Radiation 
Protection and 
Measurements 
reports that expo-
sure to potentially 
harmful ionizing 
radiat ion from 
medica l proce-
dures has seen a 
more than seven 
f o l d  i n c r e a s e 
between the early 1980s and 2006.1,2 
“The total number of CT examinations 
performed annually in the US has risen 
from approximately 3 million in 1980 
to nearly 70 million in 2007 … greater 
use of CT has resulted in a concurrent 
increase in the medical exposure to ion-
izing radiation.”3 “During conventional 
CT guided interventions, operation 
of the CT scanner is performed at 
 BI-RADS Category Total Lesions Cancerous Lesions PPV
 4 118 37 37/118 (31%)
 4a 205 16 16/205 (8%)
 4b 72 22 22/72 (31%)
 4c 43 38 38/43 (88%)
 5 69 68 68/69 (99%)
 Total 507 181 181/507 (36%)
TABLE: Frequency of Cancer and PPV as a Function of BI-RADS Category. Bolded and unbolded PPV values were 
found to be statistically significant with p-values<0.02 and p<0.001, respectively.
and 5, 97% (143/148). There was also 
a statistically significant increase in the 
cancer rate among masses (Table). 
BI-RADS 4 subcategories 4a/b/c 
may be useful predictors of malignancy 
for mass lesions. Further investigation, 
including analysis of specif ic lesion 
features, will assist radiologists in making 
evidence-based recommendations for 
use of BI-RADS subcategories 4a/b/c, 
enhancing communication, practice, 
and research.
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for lesions with moderate likelihood 
of malignancy; and category 5 lesions 
for highly suggestive of malignancy (> 
95%).1 Statistical analysis was performed 
using chi-square and Fisher’s exact tests. 
Among 1,314 lesions, 382 (29%) were 
assigned BI-RADS category 4 without 
subcategorization, 451 (34%) 4a, 241 
(18%) 4b, 88 (7%) 4c, and 152 (12%).5 
Histopathology results were available for 
1,233 lesions in 1,216 women (92.3% 
follow-up). The cancer rate in these 
1,233 lesions was 36% (441/1,233). The 
cancer rate did not differ significantly 
between lesions classified as BI-RADS 
category 4 without subcategorization 
(104/341 = 30%) vs. the sum of all 
lesions classified as BI-RADS 4a, 4b, 
and 4c (194/744 = 26%) (p = 0.2). As 
expected, the cancer rate increased 
significantly (p<0.001) with increasing 
BI-RADS subcategory: the cancer rate 
for subcategory 4a was 13% (58/433); 
4b, 29% (64/223); 4c, 82% (72/88); 
Occupational Radiation Exposure of Interventional Radiologists  
and Staff During Performance of Biopsies Guided by CT Fluoroscopy
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Center
the operating console outside the CT 
imaging room.”4 Images are captured 
while all personnel step out of the 
imaging room to the control area- a 
protected location behind leaded glass, 
thus greatly reducing if not eliminating 
the risk of exposure to ionizing radiation. 
During CT fluoroscopy however, 
connection of a footswitch and control 
panel directly to the gantry of the CT 
scanner, require the physician operator 
to stand in the CT suite while images 
are acquired, imposing the risk of occu-
pational radiation exposure.4 Personnel 
who work in fluoroscopy suites routinely 
wear leaded gowns to minimize their 
occupational exposure to radiation. 
Other dose mitigating strategies include 
staying as far away as possible from the 
X-ray source-inverse square law. Some 
studies have shown substantial radia-
tion exposure to operators who use CT 
fluoroscopy. Our objective was to study 
the amount of radiation reaching the 
physician and nurse when they stand in 
positions typical of daily work.
With an anthropomorphic operator 
phantom positioned 80cm from the 
gantry (Close), 160 cm from the gantry 
(Far), and at the side of the CT unit 
(Side), CT fluoroscopy was performed 
at the patient phantom’s upper abdomen 
using typical machine settings of 60 mA 
and 120 kV. Radiation dose was recorded 
at the operator’s: lens (with and without 
leaded 0.75 mm lead equivalent eye-
glasses), neck (with and without thyroid 
shield), left chest wall (with and without 
leaded apron), and left side (to simulate 
extremity dose) using a solid-state dosim-
eter. Measurements were then repeated 
with the operator phantom in the posi-
tion typical of a nurse in a fluoroscopy 
RADIATION EXPOSURE 
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Ratio Exposure to DLP (µR / mGy cm) 
 Locations 80 cm 160 cm 350 cm Side
 Eye Unprotected 22.15 6.81 1.30 0.85
 Eye Protected (Glasses) 2.97 0.75 0.00 0.00
 Eye Protected (Shield close to CT) 1.17 4.04    
 Eye Protected (Shield 10 cm from face) 0.40 0.00    
 Eye Unprotected (Rad Pad) 21.13 4.32 1.04 0.76
 Eye Protected (Glasses and Rad Pad)   0.57    
 Neck Unprotected 9.66 5.44 1.24 0.55
 Neck Protected  0.94 0.40 0.00 0.00
 Neck Protected (Shield close to CT) 0.00 0.00    
 Neck Protected (Shield close to face)   0.00    
 Left Breast Protected (Apron) 0.69 0.00 0.00 0.00
 Left Arm Unprotected 17.94 3.97 0.83 0.00
 Left Arm Protected (Shield close to CT) 6.82 3.57    
 Left Arm Protected (Shield close to body)   0.33    
 Left Arm Unprotected (Rad Pad) 14.16 2.94    
TABLE: CT Dose Index (CTDI): A characterization of absorbed dose, measured in a homogenous phantom by a 
diagnostic medical physicist during quality assurance, quality control experiments; units are mGy.
Dose Length Product (DLP): An approximation of the total energy a patient absorbs from the scan; units are mGy cm. 
microRoentgen (µR): A unit of radiation exposure, obtained by measuring the amount of radiation required to liberate 
a certain amount of charge in a known volume of air.
RADIATION EXPOSURE 
 Continued from p. 27
suite, approximately 350cm from the 
gantry (Nurse). Measurements were 
repeated with disposable tungsten-anti-
mony drapes (0.25 mm lead equivalent) 
on the patient phantom, and suspended 
transparent leaded shields (0.5 mm lead 
equivalent) positioned at the gantry, and 
at 10 cm from the operator lens. 
Results were expressed as the ratio 
of scattered dose received by the oper-
ator phantom (μR) to the radiation 
dose delivered to the patient phantom 
(mGy cm). The shielding efficacy of each 
strategy is expressed graphically.
Our findings show that operator dose 
was minimized by stepping to the side of 
the CT scanner when CT images were 
being obtained. The profile of scattered 
radiation from the CT scanner and the 
shielding effect of the machine housing 
are the best explanations for this obser-
vation. Nurse doses at 350 cm from the 
midpoint of the gantry were similar to 
maximally protected physician doses, 
and likely due to the mechanism pre-
dicted by the inverse square law.
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High Levels of Intra-tumoral Tumor-infiltrating Lymphocytes and No  
Angiolymphatic Invasion Increase Recurrence-free Survival in Stage 1A NSCLC. 
The presence of 
tumor infiltrating 
lymphocytes 
(TILs), 
specifically 
CD8+ cytotoxic 
T-lymphocytes, 
have been found to 
increase survival 
in many forms of 
cancer, including 
NSCLC, 
endometrial, 
bile ductal, colonic, esophageal, and 
urothelial cancers, as well as melanoma 
and follicular lymphoma.1–8
The relevance of TILs in the prog-
nosis of NSCLC, however, still remains 
controversial. In this study, we compared 
the outcomes of stage 1A NSCLC with 
and without tumor infiltrating lympho-
cytes to evaluate the effects of TILs on 
recurrence and survival patterns.
From 2000 to 2009, 273 anatomic 
segmentectomies and lobectomies were 
performed on stage 1A NSCLC. Patients 
were stratif ied into TIL- and TIL+ 
cohorts based on pathological evaluation. 
Further investigation was conducted 
on the effects of TILs in patients with 
and without angiolymphatic invasion. 
Variables analyzed include overall sur-
vival, recurrence-free survival, and type 
of recurrence (locoregional vs. systemic).
Five-year recurrence-free survival 
(RFS) was significantly increased in the 
TIL+ group vs. the TIL- group (87% 
vs. 73%, p = .011) [Figure 1], more so 
in women (p = .016). The presence of 
angiolymphatic invasion (ALI) was 
associated with decreased five-year RFS 
versus patients without ALI (61% vs. 
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85%, p<.001). Significantly, in the ALI 
negative group, TIL+ patients experi-
enced a significantly increased five-year 
recurrence-free survival vs. TIL- patients 
(93% vs. 80%, p = .036). Furthermore, 
in TIL+ patients who did experience 
recurrence, locoregional recurrences rates 
were similar to those in the TIL- group, 
at 3.5% and 5.4%, respectively. Systemic 
recurrences, however, occurred in 16.4% 
of the TIL- patients and only 6.4% of 
the TIL+ patients (p = .0295). Results 
are summarized in Table 1.
High levels of intratumoral TILs are 
associated with improved recurrence-free 
survival in stage 1A NSCLC patients as 
well as a reduced likelihood of systemic 
recurrence. When angiolymphatic inva-
sion is not present, the beneficial effects 
of TILs become even more profound. 
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FIGURE: Increased 5-year recurrence-free survival in TIL+ NSCLC.
   TIL+ TIL- p
 Overall Population 87% 73% .011
 Gender   
  Male 83% 76% .219
  Female 90% 69% .016
 Age, mean years (range) 68 (40-86) 68 (46-79) —
 Procedure   
  Lobectomy 86% 74% .049
  Segmentectomy 92% 72% .133
 Histology   
  Adenocarcinoma 85% 69% .074
  Squamous Cell 90% 78% .147
  Adenosquamous — — .114
  Large Cell — — .355
  Other — — .808
 Differentiation   
  Undifferentiated/Poor 92% 76% .341
  Moderate 87% 63% .003
  Well — — —
 Size   
  <2cm 93% 73% .004
  2-3cm 79% 73% .571
 Angiolymphatic Invasion   
 ALI+ 93% 79% .126
  ALI- 68% 56% .036
 Recurrence Location (frequencies)   
  Distant/Systemic 6.36% 16.42% .030
  Locoregional 3.5% 5.4% .555
TABLE: Five-year Recurrence Free Survival Characteristics
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Functional and Structural Connectivity of Language and Working Memory 
in Children with Epilepsy
Epilepsy is one 
o f  t h e  m o s t 
common serious 
neurological 
conditions 
affecting pediatric 
populations.1 
Seizure foci play 
a n  i mp or t a nt 
ro l e  i n  t e r m s 
o f  r e s u l t i n g 
cognitive 
impairments or changes that can occur 
in these patients.2 Recent studies have 
found that white matter tracts have 
shown immature myelination patterns 
in children with developmental and 
cognitive delays.3 DTI has been used to 
measure white matter tract integrity by 
measuring directionality and degree of 
water molecule movement in the brain.4
In epileptic patients with a localized 
seizure focus, functions of the affected 
hemisphere may latera lize to the 
contralateral hemisphere. Subsequent 
higher FA values (implying white 
matter tracts with a greater degree 
of myelination) are observed in the 
contralateral hemisphere.5 Our cross-
sectional study compared 15 controls 
to 16 pediatric epilepsy patients with 
left hemisphere focal seizures. We 
hypothesized that these patients would 
have decreased FA values in the left 
frontal lobe.
Scanned images were rated for 
quality and FSL software was used; 
images were pre-processed and the “most 
representative” FA image was identified. 
All subjects’ FA images were aligned to 
this target image. TBSS was used to 
generate a standard-space images for 
all subjects and then merge these into 
a single 4D image from which a mean 
FA skeleton was constructed. Voxelwise 
statistics were performed and using 
the Johns Hopkins white matter atlas 
in FSL, our data showed increased FA 
values for patients in the following R 
hemisphere structures: 
➤➤ Anterior internal capsule: con-
nections implicated in working 
memory, learning, fine motor skills
➤➤ Retrolenticular internal capsule: 
optic tract connections
➤➤ Corona radiata (anterior, superior): 
associated with reading ability
➤➤ Posterior thalamic radiation: 
connections between thalamus and 
parietal, occipital lobes
T he se  s t r uc t u re s  for  wh ich 
patients have higher R side FA values 
are implicated in reading, working 
memory, etc., supporting the hypothesis 
that patients with L sided lesions are 
more likely to rely on R side white 
matter to perform cognitive functions, 
which become increasingly organized 
throughout childhood. However, there 
was no accompanying decrease in 
the FA values of the corresponding 
L side structures. Patients showed 
bilateral increased FA in the genu of 
corpus callosum and superior cerebellar 
peduncles, as well as a bilateral increased 
FA in the fornix — which has been 
previously reported in other studies.6
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FIGURE 1: Blue: patient FA > control FA
FIGURE 2: Blue: control FA > patient FA
FIGURE 3: Blue: patient FA > control, in right 
hemisphere
Meera Cheerharan, MSII 
Advisor: Madison M. 
Berl, PhD, Children’s 
National Medical Center
CLINICAL PRACTICE 31
25-OH Vitamin D Levels in Patients with Retinal Pathology: A Retrospective Study 
Vitamin D defi-
ciency has now 
been recognized 
a s a pandemic 
and low serum 
levels have been 
associated with 
a mult itude of 
diverse adverse 
hea lth ef fects.1 
In addition to its 
well-established 
role in calcium regulation, Vitamin 
D also has antioxidant, immuno-
modulatory, anti-inf lammatory, and 
anti-angiogenic properties,2,3 all of 
which are mediated by the Vitamin 
D receptor.4 Although the Vitamin D 
receptor has been demonstrated to be 
highly expressed in the human retina,5 
the association between serum vitamin 
D levels and retinal health has not been 
established. In regard to retinal disease, 
two studies have shown Vitamin D 
serum levels to be inversely correlated 
with diabetic retinopathy and a possible 
protective role in age related macular 
degeneration.6,7 However, the associa-
tion between serum Vitamin D levels 
and retinal occlusive diseases has not 
been demonstrated.
Our retrospective study looked at 
565 patients diagnosed with either dia-
betic retinopathy, age related macular 
degeneration or retinal vascular occlu-
sive disease over the past five years and 
compared 25-OH vitamin D levels 
drawn during the same time period. 
These patients were subcategorized by 
disease type and severity, and 25-OH 
vitamin D levels were compared with an 
age- and gender-matched control group 
of patients seen in our ophthalmology 
department without the aforementioned 
diagnoses. In patients with multiple 
levels taken, the earliest level was used 
in an attempt to use levels taken before 
Vitamin D supplementation therapy 
was initiated. Exclusion criteria included 
patients on 1000 IU or greater daily 
dose Vitamin D. Results were compared 
using student t-tests.
Our study showed that patients with 
diabetic retinopathy (p<0.0001), retinal 
vascular occlusive disease (p<0.035) and 
the combined disease group (p<0.004) 
had significantly lower serum 25-OH 
vitamin D levels when compared to 
patients without retinal pathology 
(Figure). To the best of our knowl-
edge, this is the first report comparing 
Vitamin D levels and retinal vascular 
occlusive disease. No statistically sig-
nificant difference in serum 25-OH 
vitamin D levels was observed in 
patients with dry versus wet age related 
macular degeneration (p<0.41) or 
nonproliferating diabetic retinopathy 
versus proliferating diabetic retinopathy 
(p<0.66). There was also no significant 
difference in levels of patients with 
age related macular degeneration as a 
whole compared to patients without 
retinopathy. Further study is needed to 
identify whether vitamin D can be used 
as a marker for these conditions and if 
supplementation has any role in altering 
disease development or progress.
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Strengthening the Safety Net: Evaluating Access to Primary Care  
in the Emergency Department
Uninsured and 
low-income 
pat ient s  of ten 
r e l y  o n  t h e 
“safety net” for 
their medical care 
which includes 
local community 
health centers or 
low cost clinics, 
hea lth depa r t-
ment services, and 
local emergency 
departments 
(ED).1 In Prince 
George’s County the safety net system 
is particularly limited because of a lack 
of adequate primary care providers and 
facilities to serve the counties’ 80,000 
uninsured patients.2 Many of these 
patients resort to using the ED for rou-
tine medical care or conditions that are 
preventable with consistent outpatient 
primary care.3 Although patients can 
receive treatment in the ED for any 
health issue, the long term benefit of 
care delivered in the ED is limited by the 
lack of appropriate follow-up for patients 
without a primary medical physician.4 
This is particularly important in our low 
income chronically ill population where 
access to regular care could significantly 
improve health status and reduce avoid-
able ED visits. 
“Strengthening the Safety Net” was 
proposed to determine if direct primary 
care referral and appointment sched-
uling from the emergency department at 
point of service would increase rates of 
primary care follow up from the Prince 
George’s County ED. Furthermore, the 
study sought to assess the self described 
perceived barriers to primary care in the 
uninsured ED population. 
A randomized prospective pilot study 
of ED adult patients was conducted. A 
direct scheduler was placed in the ED 
from 9 a.m to 5 p.m., Monday through 
Friday to coordinate discharge follow 
up for intervention patients. English 
speaking patients without a primary 
care physician who required follow up 
with a PCP within a three-week time 
frame were invited to participate. At 
discharge, the intervention group had a 
follow-up appointment made with either 
of two participating low-cost clinics 
and the control group was given the 
routine discharge contact information 
and instructions to schedule a follow-
up appointment. All participants were 
called one month after their ED visit 
to ascertain if they followed-up and to 
discuss barriers to follow-up. Clinics 
were also called to verify appointment 
attendance. A proportional t-test was 
used for comparison of data.
Sixty-six patients were enrolled in 
this study over a period of one month. 
Demographic characteristics and disease 
severity were similar between the inter-
vention and control groups. Follow-up 
rates were 29% for the intervention 
group and 40% for the control group 
(P = 0.25); there was no difference 
in follow up between the two clinics 
in the intervention group.  The most 
common reason for not following up 
for both groups was a lack of transpor-
tation (13%), resolution of symptoms 
(13 percent), and work conflict (13%). 
Interestingly, patients with chronic 
medical complaints were more likely 
(30% vs. 9%, p = 0.03) to follow up 
with an outpatient clinic. Overall results 
indicated that while providing a sched-
uled appointment upon discharge from 
the ED did not improve compliance 
with outpatient follow up, patients with 
chronic medical complaints were more 
likely to obtain follow up. 
The l imitat ions of this study 
included a small study population, 
and differences in the services offered 
between the two community clinics. 
The implications of this study promote 
further collaboration between emer-
gency medicine and the community 
health center network in Prince George’s 
County, and there are currently policy 
discussions at the administrative level 
of the ED and the community clinics 
to the benefits and drawbacks of the 
results of this pilot study. Furthermore, 
the study warrants further investigation 
into efficacious program development 
and implementation in targeting the 
uninsured population that utilized the 
ED for ambulatory primary care visits. 
Subsidized transportation options and 
flexibility of appointment hours may 
contribute to higher compliance with 
outpatient follow-up among this at risk 
population. Also, the development of 
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 Complaints With No Follow-up Complaints With Follow-up
 Intervention Control Total % Intervention Control Total % p value
 Acute 19 20 39 (88.64) 7 11 18 (66.67) 0.03
 Chronic 4 0 4 (9.09) 4 4 8 (29.63) 0.03
TABLE 1: Follow up results of patients with either chronic or acute medical conditions.
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urgent care centers or services within 
the community health network is a 
perceived need, as many patients didn’t 
follow up with a PCP due to absolving 
symptoms at time of follow-up. It is 
possible that there was higher follow 
up rate in those patients with chronic 
conditions because of the ongoing need 
for affordable continuity of care.
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  Intervention % Control % Total %
 Forgot Appointment 2 (16.67) 1 (5.26) 3 (9.68)
 Lack of Transportation 4 (33.33) 0 (0.00) 4 (12.90)
 Lack of Childcare 0 (0.00) 0 (0.00) 0 (0.00)
 Lack of Eldercare 1 (8.33) 0 (0.00) 1 (3.23)
 Work Conflict 4 (33.33) 0 (0.00) 4 (12.90)
 Language Barrier 1 (8.33) 1 (5.26) 2 (6.45)
 Symptoms Better 3 (25.00) 1 (5.26) 4 (12.90)
 Inconvenient Hours — 2 (10.53) 2 (6.45)
 Cost — 1 (5.26) 1 (3.23)
 Location — 2 (10.53) 2 (6.45)
 Other 0 (0.00) 5 (26.32) 5 (16.13)
TABLE 2: Reasons for lack of follow-up.
Head Injury and Posttraumatic Stress Disorder Among Those Present South  
of Chambers Street in Manhattan During the Sept. 11, 2001 Terrorist Attacks
Man-made disas-
ter s  leave s ig-
ni f icant level s 
of stress on the 
exposed popula-
tion, and studies 
have shown that 
the mental health 
effects go beyond 
short-term stress 
and a f fect the 
popu lat ion on 
multiple dimen-
sions. The ter-
rorist attacks of 
Sept. 11, 2001, 
have been associated with a variety of 
adverse health outcomes in the exposed 
population such as asthma and other 
respiratory conditions. The World Trade 
Center Health Registry, a Bureau of the 
New York City Department of Health 
and Mental Hygiene, was created to 
investigate the long-term health effects 
of the Sept. 11 attacks and has conducted 
multiple research projects following its 
inception. The baseline survey of 71,437 
individuals exposed to the disaster, 
conducted between 2003 and 2004, 
reveals a prevalence of Posttraumatic 
Stress Disorder (PTSD) of 15.5% among 
lower Manhattan residents.4 PTSD has 
been associated with multiple exposures 
resulting from the attacks,3 with head 
injuries being of special interest, as the 
physical and cognitive consequences of 
such an injury may be related to later 
development of PTSD. 
The relationship between PTSD and 
head injury has been a subject of great 
debate within the literature, both empir-
ically and theoretically. Many studies 
have reported associations between head 
injury and PTSD, including a study of 
Oklahoma City bombing survivors.8 
Other studies have concluded PTSD 
cannot develop following a Traumatic 
Brain Injury (TBI),7 and some have even 
Sarah Mohajeri, MSI 
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concluded that severe TBI is protective 
against PTSD.5 None of these involved 
World Trade Center survivors. To 
examine this issue we investigated the 
relationship between head injury and 
PTSD outcome. 
This study focused on a sub-sample 
of registry enrollees who were physi-
cally present in the eligible area south 
of Chambers Street in Manhattan, 
between the time of the f irst plane 
impact and noon (n=43,487) [The two 
plane crashes occurred about a half-hour 
apart.]. The baseline survey collected 
information on head injury and several 
measures of mental health, including 
the PTSD Check-list (PCL) Civilian 
Version.1,6 Exposure to head injury was 
measured by asking respondents if they 
experienced a concussion. Head injury 
was one of seven specified categories of 
physical injury.
Our study found that head injury 
was a significant and strong predictor 
of PTSD (Adjusted OR=5.2, 3.8-7.1) 
within the population that was present 
south of Chambers Street during the ter-
rorist attacks. Based on previous research 
on this population,3 we controlled for 
the witnessing of horrific events, dust 
cloud exposure, age, income, ethnicity, 
and gender as possible confounding vari-
ables. Our findings were consistent with 
literature that supports the association 
between TBI and PTSD. 
Findings from this study may help 
future investigators to further examine 
the relationship between head injury and 
stress disorders, and to focus on possible 
mechanistic processes that may be 
responsible for the observed association. 
The persistence of mental illness2 among 
the population exposed to the terrorist 
attack on Sept. 11 highlights the need 
to provide treatment options and access 
to medical resources to those who have 
experienced traumatic events. 
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 Model 1 Model 2 Model 3 Model 4† Model 5††
 Crude OR Crude OR Adjusted OR Adjusted OR  Adjusted OR 
 (95% CI) (95%t CI) (95% CI) (95% CI) (95% CI)
 Head Injury 8.2 (6.3–10.8) – 7.4 (5.6–9.7) 5.2 (3.8–7.1) N/A*
 Witnessing  – 3.0 (2.7–3.5) 3.0 (2.7–3.3) 2.3 (2.0–2.5) 2.3 (2.0–2.5) 
 Horrific Events
 Dust Cloud – 1.8 (1.7–2.0) 1.8 (1.7–2.0)
 Age 0–17 1.0 1.0
  18–24 1.8 (1.2–2.8)** 1.8 (1.2–2.8)**
  25–44 3.7 (2.5–5.6) 3.7 (2.5–5.6)
  45–64 4.4 (2.9–6.7) 4.4 (2.9–6.6)
  65+ 2.2 (1.4–3.4)*** 2.2 (1.4–3.4)***
 Gender Male 1.0 1.0
  Female 1.4 (1.3–1.5) 1.4 (1.3–1.5) 
 Ethnicity White 1.0 1.0
  African American 1.5 (1.4–1.6)  1.5 (1.4–1.6) 
  Hispanic 2.2 (2.0–2.4)  2.2 (2.0–2.4) 
  Asian 1.0 (0.9–1.1)* 1.0 (0.9–1.1)* 
  Multiracial 1.8 (1.4–2.1)  1.8 (1.4–2.1) 
  Other 2.1(1.6–2.7)  2.1 (1.6–2.7)
 Income less than $25,000 4.8 (4.2–5.4) 4.8 (4.2–5.4)
  $25,000–$75,000 2.3 (2.1–2.6)  2.3 (2.1–2.6)
  $75,000–$150,000 1.4 (1.2–1.5)  1.4 (1.2–1.5) 
  $150,000 or more 1.0 1.0
 Witnessing    
  Horrific Events*   N/A* 
 Head Injury
 P<0.0001 except *(p>0.05), **p<0.01, ***p<0.001.
 Model 1: univariate logistic model, head injury as single predictor variable, PTSD as outcome. 
 Model 2: univariate logistic model, witnessing horrific events as single predictor variable, PTSD as outcome.
 Model 3: bivariate logistic model, head injury and witnessing horrific events as predictor variable, PTSD 
as outcome. 
 † Hosmer and Lemeshow Goodness of Fit Test statistics: Chis-quare=16.1 DF=8 p<0.041. 
 †† Hosmer and Lemeshow Goodness of Fit Test statistics: Chis-quare=16.2 DF=8 p<0.040.
TABLE: Crude and adjusted odds ratios for association between head injury and PTSD in World Trade Center Health 
Registry enrollees using univariate and multivariate logistic regression Analysis, with terms for interaction between 
head injury and witnessing horrific events.
2. BRACKBILL RM, HADLER JL, DIGRANDE L, EKENGA CC, 
FARFEL MR, FRIEDMAN S, PERLMAN SE, STELLMAN SD, 
WALKER DJ, WU D, YU S, THORPE LE. (2009). “Asthma 
and Posttraumatic Stress Symptoms five to six 
Years Following Exposure to the World Trade 
Center Terrorist Attack.” JAMA 302: 502–516.
3. DIGRANDE L, PERRIN MA, THORPE LE, THALJI L, MURPHY 
J, WU D, FARFEL M, BRACKBILL RM. (2008). “Post-
traumatic stress symptoms, PTSD, and risk 
factors among lower Manhattan residents 2–3 
years after the Sept. 11, 2001 terrorist attacks.” 
Journal of Trauma Stress 21(3):264–73.
4. FARFEL M, DIGRANDE L, ET AL. (2008). “An Overview 
of 9/11 Experiences and Respiratory and 
Mental Health Conditions among World Trade 
Center Health Registry Enrollees.” J Urban 
Health 85(6): 880–909.
5. KING NS. (2008). “PTSD and traumatic brain 
injury: Folklore and fact?” Brain Injury 22(1), 
1–5. 
6. RUGGIERO KJ, DEL BEN K, ET AL. (2003). “Psycho-
metric properties of the PTSD Checklist-
Civilian Version.” J Trauma Stress 16(5): 
495–502.
7. SBORDONE RJ, LITER JC. (1995). “Mild traumatic 
brain injury does not produce post-traumatic 
stress disorder.” Brain Injury. 9(4):405–12
8. WALILKO T, NORTH C, ET AL. (2009). “Head injury 
as a PTSD predictor among Oklahoma City 
bombing survivors.” J Trauma 67(6): 1311-9.
SEPT. 11 Continued from p. 33
PUBLIC HEALTH 35
Traditional Birth Attendants: A Non-Traditional Way to Improve Access to Prevention 
of Mother-to-Child HIV Transmission Efforts among Women in Rural Southern India
Comprising 
approximately 
one-sixth of the 
w o r l d ’s  t o t a l 
population, India 
has faced a host 
of medical and 
socioeconomic 
issues, including 
access to maternal 
health care and 
a rising human 
immunode-
f ic ienc y  v i r u s 
(HIV) epidemic. 
The prevalence of HIV/AIDS among 
the total adult population is 0.36%, 
with an estimated 2.5 million people 
currently living with HIV/AIDS.1 In the 
State of Karnataka in Southern India, 
the primary mode of HIV transmis-
sion is heterosexual contact, and HIV 
prevalence is estimated to be 0.69% 
among the general population. Notably, 
HIV prevalence at antenatal care (ANC) 
clinics in Karnataka State has exceeded 
1% in recent years.2 
A particular challenge to the HIV 
epidemic in India has been access 
to maternal care for HIV-infected 
women of reproductive age. In many 
rural areas of Karnataka State, less 
than 10% of all HIV-infected women 
receive ANC services, including access 
to antiretroviral medication during 
pregnancy and delivery to decrease the 
risk of mother-to-child transmission 
of HIV. Traditional birth attendants 
(TBA) attend many home deliveries in 
these rural communities, yet TBA do 
not receive training for prevention of 
mother-to-child transmission of HIV 
(PMTCT). 
In this study, we examined the preva-
lence of TBA-assisted births and the pro-
vision of ANC in a large village-based 
population sample in the subdistrict of 
Mysore, India. Using enumerated data 
on village households, we conducted a 
population based door-to-door survey 
of a random sample of rural villages 
from August to September 2008. 
Sociodemographic data were collected 
from each household, including the 
mother’s age at first childbirth, number 
of children below six years of age in 
the household, place of delivery, who 
assisted each delivery, and whether ante-
natal care was received. Multivariable 
logistic regression was used to assess 
factors associated with receiving ANC. 
The study was conducted by Public 
Health Research Institute (PHRI) in 
Mysore, India and received funding 
from the Elizabeth Glaser Pediatric 
AIDS Foundation. 
Among 16 villages, we surveyed 
1,342 households (94.4% response 
rate). The median age of women at first 
delivery was 19.5 years (range 11–46 
years). Among all children under six 
years of age, 39.3% were delivered at 
home versus 60.7% in a hospital/clinic. 
Deliveries were assisted by a doctor or 
nurse (62.7%), TBA (31.1%), relative 
(5.8%), and other (0.4%). In multivari-
able analysis, factors independently 
associated with receiving ANC included 
institutional delivery (odds ratio [OR] 
13.0, 95% confidence interval [CI]: 
8.4–20.1) and high socioeconomic status 
(OR 2.7, 95% CI: 1.8–3.9).
Our data showed that a substantial 
proportion of women delivering at home 
were less likely to receive antenatal care 
and HIV prevention services. As we 
continue to confront the HIV epidemic 
in India with a multipronged and open-
minded approach, particularly in rural 
areas, TBA performing home deliveries 
might serve as key community members 
to increase access to ANC services for 
women who do not receive care in hos-
pitals. Identifying and training TBA in 
HIV prevention strategies might allow 
for an alternative means to improve 
access to health care in these hard-to-
reach populations.
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Neglected trop-
i c a l  d i s e a s e s 
(NTDs) repre-
sent one of the 
greatest economic 
and health bur-
dens experienced 
by the people of 
Rwanda .  Data 
from 2008 found 
t h a t  6 6 %  o f 
the school-aged 
population was 
i n f e c t e d  w it h 
soil-transmitted helminthes (STHs), 
including ascariasis, trichuriasis, and 
hookworm. In some districts in the 
Northern Province, the prevalence 
among school children surpassed 90%.1 
Parasitic infections are reported by 
health centers to be the second most 
frequent reason for outpatient visits.2
With support from Legatum, an 
international investment group, and in 
collaboration with the Global Network 
for Neglected Tropical Diseases, the 
Access Project and Ministry of Health 
joined forces to develop an integrated 
NTD education and treatment cam-
paign to lower the burden of STHs 
and schistosomiasis. The purpose of 
this community-based research was to 
evaluate community perceptions of the 
current control efforts as well as knowl-
edge of STHs and schistosomiasis. 
We conducted 122 interviews in 
the districts of Musanze and Burera, 
two regions of northern Rwanda that 
received recent mass drug administra-
tion (MDA) against STHs and schis-
tosomiasis. The interviews consisted 
predominantly of open-ended questions 
and specific multiple-choice questions. 
The total sample size included 60 chil-
dren and 62 adult volunteers, including 
community health workers, health 
center staff, teachers and parents.
Results indicated that both children 
and adults regard infection with STHs 
and schistosomiasis as a significant issue. 
Over 75% of health center staff and 
community health workers identified 
intestinal worms as their first or second 
priority medical concern, compared to 
HIV/AIDS, tuberculosis, malaria and 
pneumonia. Adults identified several 
consequences of worms, including 
delayed physical development, promo-
tion of poverty and absence from school. 
Poverty was cited as the most common 
barrier to prevention. Additionally, com-
munity health workers reported many 
people not following advice on NTD 
prevention because it was impractical or 
not considered important. These results 
suggest that strengthening the message 
of behavior change and reinforcing the 
deleterious effects of worm infections is 
critical to the future of the campaign. 
Larger issues, such as access to clean 
water and resources must be confronted 
in order to achieve a long-term impact 
in NTD control. 
Nearly all the children interviewed 
believed they had been infected and 
treated. They understood the causes of 
infection and symptoms, which they had 
learned primarily through school. The 
vast majority of the children were “very 
worried” about infection and reported 
that they were practicing the recom-
mended behaviors to prevent infection. 
Most (73%) reported hand washing 
before eating, but far fewer (45%) 
reported hand washing after using the 
toilet, indicating a need for a targeted 
education campaign. 
Overall, our data suggest that among 
a sample of adults and children in 
Northern Rwanda there is a basic 
knowledge of the risks of NTDs and 
that current control efforts are accepted. 
Although this study has several limita-
tions, including reporting bias and small 
sample size, we believe it highlights the 
major attitudes expressed by the com-
munity. Further research is needed to 
better understand the direct impact of 
NTDs on school attendance, economy, 
and child health and development in 
Rwanda. 
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